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ABSTRACT 
 
Kimberly Monahan:  Characterization of Ras-driven Melanoma:  Understanding 
the relationship between acute loss of p16Ink4a and somatic activation of Ras in 
melanomagenesis 
 
(Under the direction of Dr. Norman Sharpless) 
 
Melanoma is a complex and heterogeneous disease.  It is the only cancer with an increase 
in incidence over the last three decades, which is still continuing to rise, most likely due 
to an increase in sun exposure.  Melanoma is known for its aggressive behavior, 
proclivity to metastasize and its remarkable resistance to conventional therapies.  
Melanoma is curable through surgery if caught early; however, progressive forms of this 
disease have less treatment options available.  Only one FDA-drug is approved for 
treatment of metastatic disease (dacarbazine), which has a low success rate, with one in 
ten patients responding.  The alarming rate of incidence and the continue failures of 
treatments, has left an urgency to better understand both the genetic and environmental 
factors involved in the pathogenesis of melanoma in order to develop more effective 
therapeutic agents.  To date genetically engineered mouse models of melanoma exploit 
the use of both transgenes and germline knockout alleles which inherently do not reflect 
the somatic mutations commonly found in human melanoma.  The p16INK4a-CDK4-RB 
and ARF-p53 tumor suppressor pathways are compromised in nearly all human 
melanomas.  While heterozygous germline mutations of p16INK4a are associated with 
familial melanoma, most melanomas harbor somatic p16INK4a loss, with a significant 
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minority also harboring somatic p53 inactivation.  Here, we employ a novel p16INK4a 
conditional allele along with conditional p53 and K-Ras alleles to better model human 
melanoma.  We found that there is potent synergy between melanocyte-specific loss of 
p16INK4a and/or p53 with activation of K-Ras in melanomagenesis. 
Melanoma is recognized as one the most immunogenic cancers.  
Immunotherapies have been developed to target metastatic melanoma by using treatments 
to boost the suppressed immune response; however they have shown a low response rate.  
Here we show that CD200, a negative regulator of the immune system, is overexpressed 
in melanoma and helps melanoma evade an immune response.  Therefore, we believe that 
melanoma is a rational target of CD200-CD200R anti-cancer therapies. 
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Chapter 
I.  Introduction: The Genetics and Pathogenesis of Melanoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Melanoma is the most lethal form of skin cancer, accounting for approximately 
75% of deaths caused by skin cancer each year (1).  It has become an international 
epidemic with an alarming incidence rate which has steadily increased over the past few 
decades.  In the United States, melanoma represents the 5th most common cancer for men 
and the 6th most common cancer for women (National Institute Cancer Facts 2008).  
Melanoma affects many young men and women; with its greatest effect on women 
between 25 to 45 years of age.  Over the last few decades the incidence rate of melanoma 
has doubled and is continuing to rise, most likely due to increased recreational exposure 
to ultraviolet-B (sunlight) (1).  While melanoma can be cured by surgery if caught early, 
conventional therapy, such as radiation and chemotherapy, have little success with 
treating progressive forms of this disease.  To date, an effective therapy has yet to emerge 
from the medical field; the current FDA-approved melanoma drug (dacarbazine) has low 
success rate with only 1 in 10 patients responding to treatment.  Even though the outlook 
for treating melanoma appears dismal, new pathogenetic understandings and new 
therapies are generating an improved future for melanoma patients.   
Retrospective epidemiological studies have indicated that there is a strong 
relationship with increase sun exposure and a higher risk for developing melanoma  (2).  
There is much debate over the time of sun exposure during a lifetime and how it affects 
the risk of developing melanoma.  Some studies have shown that intense sun exposure at 
an early age increases the risk of melanoma while sun exposure in adulthood has little to 
no effect (3-6).  Other studies have shown that lifetime sun exposure and sunburns during 
holidays have a greater risk for melanoma.  The incidence of melanoma is one of the few 
cancers that has an incidence that is continuously rising at approximately 3% each year.  
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Introduction of tanning salons and increased sun exposure are factors why the incidence 
of melanoma has surged over the last several decades.  Melanoma affects many young 
men and women; with its greatest effect on women between 25 to 45 years of age.   
In addition to UV exposure there are other risk factors, such as physical 
characteristics that contribute to an increase risk of developing melanoma.  Studies have 
shown that light complexion, the inability to tan, red hair, blue eyes, the  number of 
freckles and nevi (RHC phenotype) are all associated with an increase risk of melanoma 
development (7-9).  The melanocortin-1 receptor (MC1R) is a major determinant of 
pigmented phenotype, which codes for a seven-transmembrane G protein-coupled 
receptor expressed on the surface of melanocytes. MC1R is highly polymorphic with at 
least 30 allelic variants found in humans (7, 10, 11).  Several of these variants are thought 
to associate with the RHC phenotype which contributes to the increase of all skin cancers 
including melanoma.  However, the Asp84Glu variant, the most significantly associated 
allele with increased susceptibility for developing melanoma, did not correlate with color 
of the skin and hair (12).  Moreover, MC1R signaling is a major component of melanin 
synthesis in response to UV damage and MCR1 variants that are deficient in melanin 
production leads to limited photo-protection and susceptibility to UV-induced damage 
(13, 14).  
While UV has been a strong carcinogen of melanocytes and specific physical 
characteristics are all risks for melanoma development, there is strong evidence that 
mutational genetic make-up and histopathological subtype can influence the pathogenesis 
of melanoma.  These findings suggest that melanoma is a heterogeneous and complex 
disease.  Exploration into the genetic profiles of melanoma subtypes and its heterogeneity 
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is important in determining rational targets and effective treatments for melanoma 
patients. 
A. Progression of Melanoma 
 The majority of melanomas arise from melanocytes located in the epidermal-
dermal junction in skin; however non-cutaneous melanomas can be found in areas such 
as the eye, gastrointestinal and genitourinary mucosal surfaces or the meninges.  
Melanocytes arise from neural crest cells, which give rise to melanoblasts, a precursor to 
melanocytes.  Melanoblasts migrate to distant areas in the body during development and 
end up in the basal layer of the epidermis and the hair follicles.  The initiation, 
progression and metastasis of melanoma are thought to develop in a systematical way. 
The typical progression of melanoma begins with a benign nevus (mole) which acquires 
mutations, usually through UV-induced DNA damage.  The nevus is thought to consist of 
a clonal population of melanocytes that are aberrantly proliferating; however it is has 
been shown that initiating mutations, such as B-RAF induces a state of senescence and 
the nevus halts its growth (15-17).  Upon further mutations, senescence is overcome and 
the nevus becomes dysplastic and progresses to superficial spreading along the epidermal 
basal layer but remains in situ and lacks the capacitiy to invade into the dermis and 
metastasize (radial growth phase (RGP)).  Finally, radial growth phase melanoma cells 
acquire the ability to invade into the dermis (vertical growth phase (VGP)) and 
disseminate to distant organs, such as the lymph nodes, brain and lung.  However, there 
are exceptions with dysplastic nevi transforming directly to vertical growth melanomas 
and invading surrounding tissues, as well as nodular melanomas which do not need a 
precursor, such as nevus, to form (Figure 1).    
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Table 1 Clincial classification of melanoma 
Subtype Frequency Distinguishing Features 
 
Superficial spreading 
melanoma 
70% Usually found in intermittent sun exposed 
areas, such as the upper back and lower 
legs, arise from a precursor (nevus) 
Nodular melanoma 15% Usually do not require a precursor 
Lentigo maligna 
melanoma 
4% - 15% Exclusively found on sun-exposed areas, 
such as the head and neck 
Acral lentiginous 
melanoma 
10% Does not seem to associated with sun 
exposure, usually found on palms, soles, 
and under the nail plate 
Desmoplastic 
melanoma 
<5% (rare) Locally aggressive, not associated with 
pigment 
The initiation, progression and metastasis of melanoma. This illustration depicts the stepwise 
manner melanomagenesis.  In response to ultraviolet radiation-induced damage normal 
melanocytes begin to aberrantly proliferate developing into a senescent nevus, which often 
harbor mutations in either N-RAS or B-RAF.  Upon additional mutations, the nevus becomes 
dysplastic and progresses into melanoma, which superficially spreads along the basal epidermal 
layer (radial growth phase).  This is followed by extravasation into the dermis (vertical growth 
phase) and eventually to metastasis to other organs. 
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There are several different subtypes of melanomas: superficial spreading 
melanoma (SSM), nodular melanoma, lentigo maligna melanoma, acral lentiginous 
melanoma (ALM), and desmoplastic melanoma.  Superficial spreading melanoma is the 
most common subtype of melanoma accounting for approximately 70% of all 
melanomas.  It usually arises from a melanocytic precursor and is found in intermittent 
sun exposed areas of the body, such as upper backs and lower legs.  Nodular melanomas 
are the second most common subtype of melanoma accounting for approximately of 15% 
of melanomas.  About 5% of nodular melanomas are amelanotic and usually do not 
require a precursor to develop.  Acral lentiginous melanoma account for about 10% of 
melanomas and are usually found on the palms, soles and beneath the nail plate.  ALM 
does not seem to associate with sun exposure.  Lentigo maligna melanoma is one of the 
least common sub-types of melanomas accounting for 4 % to 15% of patients and is 
exclusively found on sun exposed areas such as the head and neck.  Lastly, desmoplastic 
melanomas are a rare subtype that locally aggressive and have the proclivity to invade 
perineurally which often causes them to be symptomatic. 
 Clinical staging of melanoma includes the appearance, thickness and size of the 
melanoma, the presence of ulceration, evidence of melanoma in draining lymph nodes 
and evidence of distant metastasis.  Due to self-screening and regular skin examinations 
many melanomas are discovered in the early stages.  Approximately 85% of patients 
present in either stage I or stage II, 15% of patients present with regional nodular disease 
and 2% present with distant metastasis.  Early detection and diagnosis of melanoma is 
critical for its ability to be cured.  If caught early, treatment of melanoma usually consists 
of surgical removal and if needed removal of nearby lymph nodes.  However, if 
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diagnosed in later stages the survival rate decreases dramatically with a median survival 
of 6 – 9 months.  Late stage and metastatic melanoma patients have limited treatment 
options available and known for their resistance to standard treatments.   
B. Therapies 
Typical treatments include: radiation therapy, immunotherapy, and/or 
chemotherapy, however many of these treatment regimens have had few successes.  The 
most active agent is dacarbazine (DTIC), which is the only FDA-approved 
chemotherapeutic agent commonly used to treat metastatic melanoma.  However, at best 
DTIC has a 10% to 20% response rate in patients and duration of the response is short 
(18).  Temozolomide, which is similar to DTIC, can cross the blood-brain barrier; this 
treatment is used in cases of metastatic melanoma found in the brain, however it does not 
have an improved response rate when compared to DTIC (19).  The current therapies for 
metastatic melanoma have low response rates and have been largely unsuccessful; 
therefore new therapies have slowly begun to emerge, such as targeted small molecule 
inhibitors and immunotherapy (Table 2).  
Immunotherapy treatment for melanoma has been a promising field due to the 
observations that melanoma is one of the few cancers that can spontaneous regress, the 
presence of infiltrating T cells in primary melanomas and circulating T cells with 
melanoma antigens have been found in melanoma patients.  The current immunotherapy 
for melanoma consists of Interferon-α (IFN-α) and interleukin-2 (IL-2).  While both 
regimens have seen a positive response rate of 10% to 20% (20-24), the severe toxicities 
with high doses has limited the use of these immunotherapies, pushing the field to 
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develop less toxic and more effective therapies such as melanoma vaccines and CTLA-4 
monoclonal antibodies. 
Melanoma vaccines  
 Melanoma tumor antigens, such as MART1 (melanoma antigen recognized by T 
cells), tyrosinase, and gp100, can be readily found in circulating T cells of melanoma 
patients (25).  However, either due to inefficient number of these cells or an 
immunosuppressive microenvironment, the immune response is unsuccessful.  Melanoma 
vaccines may boost the immune response and allow the immune system to eradicate the 
tumors.  There are different approaches to generate a melanoma vaccine: 1) vaccines 
consisting of whole cells derived from autologous tumor cells 2) vaccines derived from 
melanoma associated peptide antigens 3) vaccines using tumor lysate to pulse dendritic 
cells with melanoma associated antigens (reviewed in (26-32)).  While there has been a 
major effort in developing melanoma vaccines many attempts have shown little efficacy 
in treatment of progressive forms of melanoma.   
CTLA-4 monoclonal antibodies 
 An effective immune response to a tumor antigen includes T cell activation in 
response to recognition of tumor-specific antigens.  T cell activation requires successful 
signaling of the T cell reporter and the costimulatory receptor CD28.  Cytotoxic T 
lymphocyte-associated antigen-4 (CTLA-4), a member of the CD28 immunoglobulin 
family, inhibits CD28-signaling by binding to CD80 or CD86, which are expressed on 
antigen-presenting cells.  Inhibition of CD28 signaling downregulates T cell activation 
and IL2 production (33).  Mice deficient for CTLA-4 showed an increase susceptibility to 
developing autoimmune diseases when experimentally challenged.  These findings have 
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produced excitement for targeting CTLA-4 in melanoma immunotherapies.  Anti-CTLA-
4 monoclonal antibodies have recently been developed and are being tested in clinical 
trials for melanoma and treatment with CLTA-4 antibodies have yielded response rates of 
7–15% in heavily pretreated patients with metastatic melanoma (32, 34-36).  While 
CTLA-4 monoclonal antibodies treatments are still being optimized to increase efficacy 
and reduce autoimmune toxicities, the clinical trials have generated a promising outlook 
for immunotherapy for melanoma patients. 
C. Mutational Analysis 
The skin is a protective organ, which acts as a barrier to keep toxic agents out and 
keep essential fluids in.  It is the first line of defense against heat, UVR, injury and 
infection. While sunlight in moderation is healthy for our skin  for the production of 
vitamin D; excessive  UV-radiation exposure is potentially dangerous because of  its 
ability to mutagenize DNA and cause mutations in critical genes (37).  The deleterious 
effects of UVR are caused by its ability to induce pyrmimdine dimers in DNA.  DNA 
repair mechanisms are prepared to fix these mutations; however incorrect repair of theses 
dimers leads to mutations.  Moreover, UVR indirectly affects cells by manipulating the 
cell cycle to leave less time to repair any damages or by reducing the levels of enzymes 
which are needed to protect against UVR.  While UVR exposure and other risk factors 
have a strong association with increase incidence in melanoma, genetic analysis of 
melanoma has now determined important oncogenic and tumor suppressor pathways that 
are commonly mutated in melanoma and thought to play an important role in the 
pathogenesis of melanoma (Table 3). 
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Table 2 Current therapies for melanoma patients 
Treatment Efficacy References 
DTIC (dacarbazine) 10% to 20% response rate 17 
Temozolomide 10% to 20% response rate 18 
Immunotherapies  
(IL2 and IFN-α) 
IL2- 13% to 17% response rate 
IFN-α - 16% response rate 
19-23 
CTLA-4 monoclonal 
antibodies 
7 % to 15% response rate 33-35 
Melanoma vaccines No effect to 25% response rate 25-31 
 
Table 3 Common tumor suppressors and oncogenes mutated in melanoma 
Gene Mutations Function 
INK4a/ARF Point mutation, 
promoter methylation, 
deletion 
p16INK4a- regulates cell cycle progression for 
G1 to S phase 
ARF- regulates p53 stabilization and activation 
CDK4/Cyclin 
D1 
Point mutations Involved in phosphorylating RB and 
promoting cell cycle  
p53 mutations Gate keeper of the genome, responds to DNA 
damage and halts cell cycle in order to repair, 
causes senescence, or induces apoptosis 
N-RAS Point mutations in 
exons 12, 13 or 61 
Small GTPase involved in many cell signaling 
networks which include: cell proliferation, 
growth, differentiation, gene expression 
B-RAF Point mutation: V600E Serine/threonine kinase which is involved in 
many cell processes: development, cell cycle 
regulation, cell proliferation, cell 
differentiation, cell survival and cell apoptosis 
PTEN Epigenetic silencing, 
deletion 
Regulates AKT activity, acts a tumor 
suppressor, involved in apoptosis, cell survival, 
cell growth and cell metabolism 
c-KIT mutation Activates several different signaling pathways: 
RAS/RAF/MEK/ERK, PI3K/AKT, 
phospholipase C, and the SRC family 
β-catenin mutation Activates gene expression involved in a variety 
of cell processes 
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p16INK4a and ARF 
Genetic analysis of familial atypical multiple molemelanoma (FAMMM) 
syndrome, a disease which has up to 1000 fold risk over the general population to 
develop melanoma, identified the CDK2Na locus as a significant melanoma susceptibility 
locus (38-40).  Loss of heterozygosity or mutation of this locus co-segregated with 
melanoma susceptibility in familial melanomas  and deletions of the CDK2Na locus are 
frequently found in somatic melanoma. The CDK2Na locus is found on chromosome 
9p21 and encodes two distinct tumor suppressor proteins:  p16INK4a and ARF which both 
play central roles in the control of the both the progression and checkpoints of the cell 
cycle.  p16INK4a inhibits the ability of cyclin dependent kinase 4 and 6 (CDK4/6) to 
phosphorylate and inactive the retinoblastoma protein (RB); therefore halting the cell 
cycle to progress to S-phase (41).  ARF (alternative reading frame), also known as 
p19ARF in mice and p14ARF in humans, regulates the p53 pathway by inhibiting MDM2, 
an E3 ubiquitin ligase, and consequently stabilizing and activating p53 function.   
CDK4  
 In addition to abrogation of p16INK4a function in melanoma, mutations in its 
target, cyclin dependent kinase 4, are found in a small subset familial melanoma patients 
(42, 43).  CDK4 is normally inhibited by p16INK4a however when the interaction between 
CDK4 and p16INK4a is abrogated, CDK4 phosphorylates RB which allows E2F to be 
translocated into the nucleus and transcribe genes needed for entry into S-phase.  A 
substantial amount of melanoma-associated germline variants in the INK4a/ARF locus 
found in FAMM interfere with the binding of p16INK4a to CDK4 while maintaining 
interaction with CDK6 (44).  However, these variants have a decrease in cell proliferation 
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in vitro, suggesting CDK4 is the important target in the pathogenesis of melanoma.  
While most variants found inhibit p16INK4a ability to abrogate CDK4 function, activating 
mutations of CDK4 (CDK4R24C), which allow it to be resistant to p16 INK4a inhibition, 
have been found in a subset of familial melanoma patients (45).  These variants leave 
CDK4 unregulated; therefore constitutively phosphorylating RB, progressing the cell 
cycle through to S phase.  Moreover, mouse models using a CDK4R24C knock in activated 
allele develop melanoma when challenged with carcinogens (DMBA, TBA) (46).   
Cyclin D1 
 Cyclin D1 stimulates the cell cycle through binding and consequently activating 
both CDK4 and CDK6.  Activation of these kinases leads to phosphorylation of RB and 
progresses the cell cycle from G1 to S phase.  Because of its interaction with CDK4 and 
CDK6 it is thought to play a role in tumorigenesis as a potential oncogene.  Increased 
cyclin D1 expression has been observed in specific subset of melanomas which arise on 
skin with chronic sun-induced damage (47).  Therefore 44% of acral melanomas, 19% of 
lentigo malignant melanomas, and 6% of superficial spreading melanomas all have an 
increase in cyclin D1 expression (48).  Recently, a subset of N-RAS/B-RAF wild type 
melanomas have shown to have an increase of cyclin D1 and c-KIT expression, 
suggesting that over expression of cyclin D1 and c-KIT is an alternative way to induce 
transformation in melanomas that harbor wild-type N-RAS/B-RAF (49).  Further analysis 
of cyclin D1 expression in melanoma demonstrated that cyclin D1 over-expression 
contributes to drug resistant to BRAF inhibitors in BRAFV600E mutant melanomas cell 
lines (50).   
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p53 
 The ARF-p53 pathway is an important tumor suppressor pathway.  While ARF 
stabilizes and activates p53, p53 itself is a potent tumor suppressor.  It is activated upon 
DNA damage and serves as a checkpoint that halts the cell cycle to allow sufficient time 
to repair any acquired damage or if the damage cannot be repaired activate programmed 
cell death (apoptosis). In response to UV-induced damage it mediates cell apoptosis and 
cell cycle arrest also regulates DNA repair through excision repair pathways(51-54).  
However, while inactivation of p53 seems to be a common mutation found in the 
majority of solid tumors, it is rarely mutated in melanoma.  Several studies have found 
either rare or absent p53 mutations or deletions in primary and metastatic melanomas.  
The role of p53 function in melanoma is only partially understood; however these data 
suggest that melanomas prefer to delete ARF to perturb the ARF-p53 tumor suppressor 
pathway instead of altering p53 function.   
N-RAS 
The RAS signaling pathway is a mitogen activating kinase cascade, which has a 
myriad of effects on the cell; however, when the pathway is aberrantly activated it 
induces uncontrolled cell growth implicating itself in a variety of cancers ((55-57)).  RAS 
controls several biological processes through different pathways:  the RAS-RAF-MEK-
ERK pathway has been implicated in cell proliferation while the RAS-AKT pathway is 
implicated in cell survival and apoptosis.  Activating mutations in RAS proto-oncogenes 
are frequently found in human cancers.  RAS mutations are found in approximately 15 % 
to 30% of all cancers.  In human melanoma, N-RAS mutations occur in approximately 
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10-20% of tumors (58, 59).  Activating N-RAS mutations have been associated with 
nodular lesions and sun exposure.  
B-RAF 
 B-RAF, the direct downstream target of RAS, is mutated in approximately 70% of 
melanomas (15, 60, 61).  Constitutively activate mutations usually occur in the kinase 
activation domain at V600E.  B-RAFV600E mutations are commonly found in dysplastic 
nevi suggesting its role as an initiating mutation and in early neoplasia.  Evidence has 
suggested that initiating B-RAF activation induces senescence in melanocytes, generating 
benign nevi(16, 62, 63).  Nevi that harbored the BRAFV600E mutation stained positively 
for senescence associated β-galactodisase, a senescence marker, suggesting that 
oncogene-induced senescence is an in vivo process that protects against the development 
of melanoma.  The common occurrence of B-RAF mutations found in nevi, suggest that 
B-RAF mutation alone is not sufficient for the development of melanoma but additional 
mutations need to occur, such as the deletion of the CDKN2a locus.  
PTEN 
 Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) is an 
important tumor suppressor involved in a variety of processes: apoptosis, cell survival, 
cell growth and cell metabolism (reviewed in (64, 65)).  PTEN is located at chromosome 
10q23 and encodes for a protein with two biochemical functions: lipid phosphatase 
activity and protein phosphatase activity.  Its main function is to decrease intracellular 
levels of phosphatidyl-inositol 3,4,5 triphosphate (PIP3) and downstream AKT activity 
regulating G1 progression and apoptosis (66).  Abrogation of PTEN through mutation, 
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deletion or promoter methylation has been seen in a variety of cancers such as 
endometrial carcinomas, breast and prostate carcinomas and melanomas (67).   
In melanoma cell lines, a PTEN mutation rate of 30-50% has been reported,                              
while a mutation rate 5-20% has been reported in uncultured melanomas (68-70).  Loss 
of heterozygosity of PTEN has been observed in approximately 30% of melanoma 
samples.  Furthermore, epigenetic studies analyzing PTEN protein expression in primary 
melanomas showed that PTEN expression was undetectable in 15% of melanomas and 
low in 50% of melanomas (71).  Analysis of melanomas undetectable for PTEN 
expression, determined that neither a deletion nor mutation of PTEN occurred, suggesting 
that an epigenetic event silenced the two PTEN alleles.  Moreover, a study employing a 
Tyrosinase CRE-ERT2 allele, a BRAFV600E conditional allele and a PTEN conditional 
knock-out allele have shown potent cooperation in the initiation, progression and 
metastasis of melanoma (72).  These finding indicate that PTEN is a potent tumor 
suppressor in melanomagenesis. 
NEDD9 
 Comparison of non-metastatic parental and metastatic variant melanoma cell lines 
in the mouse revealed NEDD9 to be the only gene on chromosome 13 which was 
amplified in the metastatic variants, suggesting that NEDD9 may play a role in the 
metastasis of melanoma (73).  Further analysis of a tissue microarray of human 
melanomas indicated a correlation between NEDD9 and tumor progression.  In vitro 
analysis showed that shRNA knockdown of NEDD9 reduced the ability of melanoma cell 
lines to migrate in the Boyden Chamber assay, suggesting NEDD9 was essential for 
invasion of the melanoma cell lines.  Further analysis demonstrated that NEDD9 motility 
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in vitro was involved with focal adhesion kinase and the formation of focal adhesions, 
which is essential in cell motility.  The use of mouse model of melanomas is now 
identifying genes that are essential for the metastasis of melanoma. 
c-KIT 
Receptor tyrosine kinases have a predominant role in transmitting signals from 
extracellular receptors to intracellular effectors.  The c-KIT gene encodes a RTK that 
serves as the receptor for stem cell factor (SCF).  Binding of SCF to the KIT receptor 
leads to activation of the KIT receptor and stimulation of several different signaling 
pathways:  RAS/RAF/MEK/ERK, PI3K/AKT, phospholipase C, and the SRC family.  
There is some controversy on the role of c-KIT in the survival, proliferation and 
migration of melanocytes.  Mice deficient for c-Kit show a decrease in the number of  
melanocytes suggesting that c-KIT is important for melanocyte survival (74).  In vitro 
studies have shown that c-KIT expression drives melanocyte proliferation and in vivo 
studies employing transgenic mice over expressing the membrane-bound form of SCF in 
the epidermis develop melanocytic hyperplasia (75).  However other studies have 
concluded that c-KIT expression does not induce proliferation but is responsible for 
migration of melanocytes (76, 77).   Furthermore, mutation analysis of c-KIT has 
recognized that distinct subgroups of melanomas harbor mutations in c-KIT with c-KIT 
mutations being reported in 36% of acral melanomas and 25% of melanomas arising 
from chronically sun-damaged skin (78-80).  Recent studies have demonstrated that a 
subset melanomas that lack N-RAS or B-RAF mutations overexpress both c-KIT and 
CDK4 and that these tumors are sensitive to imatinib treatment and resistant to B-RAF 
inhibitors (49).  These findings suggest the regulation of c-KIT is critical for maintaining 
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melanocyte homeostasis and deregulation of c-KIT signaling induces melanoycte 
transformation. 
β-catenin 
Many cancers have shown an upregulation of the Wnt signaling pathway by 
evidence of increased nuclearization of β-catenin such as colon cancer and melanoma 
(81, 82).   β-catenin is primarily found at the cell membrane where it associates with 
cadherins in forming cell to cell adhesions.  However, when it is not associated with the 
cell membrane it is phosphorylated by glycogen synthase kinase (GSK-3β) and is 
consequently ubiquintinated and degraded.  However, when Wnt signaling is activated, 
Wnt proteins interact with cell surface receptors of the Frizzled family, which then 
activate members of the Dishevelled family.  The Dishevelled (DSH) protein interacts 
with GSK-3β inhibiting its ability to phosphorylate β-catenin, which then stabilizes β-
catenin allowing it to translocate to the nucleus where it interacts with TCF/LEF 
transcription factors which stimulate specific gene expression.  Mutations found in β-
catenin often mimic the activated Wnt signaling response and β-catenin cannot be 
phosphorylate by GSK-3β  (83).  Transgenic mice deleted for exon 3 of the β-catenin 
gene, where most of the GSK-3β  phosphorylation occurs on certain serine and threonine 
residues, have an increase in tumor formation in certain tissues (84-86) .  These findings, 
suggest that stabilized β-catenin is tumorigenic.   
 β-catenin’s role in melanocytes is important in the early development of 
melanoblasts and is important for the cell fate of melanoblasts (87, 88).  Activated β-
catenin is found in low percentage of melanomas; however the activation of Wnt/β-
catenin pathway has been shown to be activated in approximately 30% of melanomas 
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(81).  Recently, a transgenic mouse model employing both a constitutively active N-RAS 
and stabilized β-catenin developed highly pigmented and metastasis melanoma at 
approximately 30 weeks(89).  Surprisingly, stabilized β-catenin was shown to silence the 
p16INK4a promoter.  This suggests that in the context of melanocytes, stabilized β-catenin 
down regulates p16INK4a and synergizes with MAPK signaling pathway to develop 
melanoma.  
D. INK4a/ARF/INK4b tumor suppressor locus 
Uncontrolled cell proliferation due to disturbances in cell cycle regulatory 
proteins occurs in a majority of cancers.  Loss of the INK4a/ARF/INK4b tumor 
suppressor locus is one of the most frequent events in many different types of human 
cancers (41, 90, 91).  The locus encompasses only a short genomic distant (35kb) of the 
human genome and encodes three distinct tumor suppressor genes: p15INK4b, p16INK4a and 
ARF (p19ARF in mice and p14ARF in humans) (92, 93).  While p15INK4b is physically 
distant and has its own open reading frame, p16INK4a and ARF have different first exons 
that are spliced to a common second and third exon.  Although p16INK4a and ARF share 
exons 2 and 3, ARF is encoded in an alternative reading frame, consequently p16INK4a 
and ARF do not share any homology and are not isoforms (Figure 2).  This unusual 
arrangement of important tumor suppressors in one locus questions how this locus 
evolved and its effectiveness in anti-cancer responses.  The selective pressures of cancer 
formation might target all three tumor suppressors or there might be no selective pressure 
and this ultimate tumor suppressor locus is not selected against (reviewed in (94, 95)).  
While it seems to inefficient to have all three tumor suppressor within 35kb of one 
another, the INK4a/ARF/INK4b tumor suppressor locus has been shown to be involved in 
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many times of cancer, the aging in certain tissues and each product can also be regulated 
through different mechanisms.  
p15INK4b
 The tumor suppressor gene p15INK4b has been the least studied gene of the 
INK4a/ARF/INK4b tumor suppressor locus.  Its tumor suppressor function has not been 
seen as important until recent studies.  Both p15INK4b and p16INK4a are members of the 
INK4 class of cell cycle inhibitors (also includes p18INK4c and p19INK4d) which abrogate 
CDK4 and CDK6 kinase function, resulting in a G1 arrest.  p15INK4b and p16INK4a share 
85% amino acid homology and there is little distinction between there biochemical 
properties.  In a recent study, mice deficient for all three tumor suppressor genes: p16Ink4a, 
p15Ink4b and Arf, had a more tumor prone phenotype and developed a wider spectrum of 
tumor types than Ink4a/Arf deficient mice, suggesting that p15Ink4b is an important tumor 
suppressor (96).  Under conditions of stress in p16Ink4a deficient mouse embryonic 
fibroblasts (MEFs),  p15 INK4b protein levels were dramatically increased, indicating that 
p15Ink4b is a critical backup mechanism response to the loss of p16Ink4a.  Moreover, recent 
analysis of p15INK4b status in certain tumor types, demonstrated that hypermethylation of 
p15INK4b in the absence of p16 INK4a hypermethylation occurred in high frequency of 
leukemias and lymphomas (97-99).  While p16INK4a and ARF have been thought to be the 
major tumor suppressors, p15INK4b is an important tumor suppressor back up mechanism 
when p16INK4a and ARF functions are abrogated. 
p16INK4a
 Located at 9p21, p16INK4a is the founding member of the INK4 family members  
(p15INK4b, p18INK4c, p19INK4d) which all have the ability to regulate the G1 to S phase 
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transition in the cell cycle (100-102).  p16INK4a inhibits the cell cycle by binding to 
 
 
 
Structure of the INK4a/ARF/INK4b tumor suppressor locus. The locus encompasses only a 
short genomic distant (35kb) of the human genome and encodes three distinct tumor suppressor 
genes: p15INK4b, p16INK4a and ARF (p19ARF in mice and p14ARF in humans).  While p15INK4b is 
physically distant and has its own open reading frame, p16INK4a and ARF have different first 
exons that are spliced to a common second and third exon.  Although p16INK4a and ARF share 
exons 2 and 3, ARF is encoded in an alternative reading frame, consequently p16INK4a and ARF 
do not share any homology and are not isoforms.  p15INK4b and p16INK4a both abrogate CDK4 and 
CDK6 kinase function and the formation of the CDK-Cyclin complex, resulting in a 
hypophosphorylated RB and a G1 arrest.  ARF binds to and inhibits MDM2, an E3 ubiquitin 
ligase.  Inhibition of MDM2, prevents the polyubiquitination and subsequent polysomal mediated 
degradation of p53.  Stabilization of p53 results in activation of p53 target genes which involved 
in cell cycle arrest, cellular senescence or cell apoptosis. 
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CDK4/6, which inhibits D type cyclins to interact with CDK4/6.  This negative 
interaction inhibits the CDK4/6-mediated phosphorylation of retinoblastoma protein 
(RB).  When RB is maintained in its hypophosphorylated state it remains bound to the  
E2F transcription factor family, which consequently halts the cell cycle in G1 preventing 
the cell cycle from transitioning to S phase.  Furthermore, analysis of INK4 family 
members during the development of the mouse, demonstrated that p16INK4a was not 
involved in regulating development but was an important player in cell cycle check point 
control (103).  The ability of p16INK4a to regulate the cell cycle contributes to p16INK4a’s 
significant roles in both cancer and aging. 
 Loss of the INK4a/ARF locus has been demonstrated in approximately 50% of 
primary melanomas (104, 105), which is also observed in other cancers such as 
pancreatic, lung and ovarian cancers.  The cyclin-dependent kinase inhibitor, p16INK4a is 
one of the gene products of the INK4a/ARF locus and its function is frequently abrogated 
through a variety of mechanism: homozygous deletion, loss of heterozygosity, intragenic 
mutations, hypermethylation of promoter regions and microsatellite instability (104, 106-
109).  Gradual loss of protein and mRNA expression of p16INK4a is associate with the 
progression of melanoma in both sporadic and familial melanoma (110-113).  p16INK4a 
loss or mutations are rarely seen in nevi and in primary melanomas suggesting that either 
p16INK4a is not an initiating mutation involved in melanocytes transformation or is not 
required for early development of melanoma (111, 114).  However, germline mutations 
of p16INK4a are found in both nevi and melanomas of familial melanoma kindreds (115), 
suggesting that p16INK4a possesses the ability to initiate transformation in some forms of 
melanomas.   
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 Germline mutations of the INK4a/ARF locus have provided key information about 
the role of p16INK4a and ARF in the susceptibility to melanoma development.  Germline 
mutations in the INK4a/ARF locus have been reported in approximately 25-50% of 
familial melanoma kindreds (38-40, 109, 116-120).  Furthermore, the geographical 
location of familial melanoma kindreds associates with a higher penetrance of mutations 
in the INK4a/ARF locus (121).  In addition to variants in the INK4a/ARF locus,  MCR1 
variants further increase the susceptibility to melanoma development in melanoma-prone 
families (122).  Strikingly, many mutations found in melanoma-prone families may only 
ablate p16INK4a function and retain normal ARF function, suggesting that p16INK4a is the 
bona fide tumor suppressor in melanoma.  CDK4 point mutations found in familial 
melanoma target its interaction with p16INK4a suggesting p16INK4a inhibition of CDK4 is 
required for tumor suppression (42, 43, 120, 123).   
 Epidemiological studies have shown that there is prominent association between 
sun exposure and lifetime risk for developing melanoma (reviewed in (124)).  UV-
induced damage is thought to disrupt melanocyte homestasis is different ways: 1) 
mitogenic affect inducing melanocytes proliferation 2) activator of paracrine factors 
which induce melanocytes proliferation 3) suppressor of the immune system in the skin 
4) global mutagen.  Analysis of p16INK4a in melanoma patients has observed the C>T 
point mutation, which is classified as a UV-signature mutation, suggesting the UV-
induced damage targets p16INK4a in melanocytes (125).  However, this point mutation in 
p16INK4a has also been seen in glioma questioning its UV-induced origins (126, 127). 
Melanocyte transformation is the first critical step in melanoma development.  In 
order to prevent this process, p16INK4a has shown to be a important tumor suppressor and 
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promote senescence in fibroblast and melanocytes (128-130).  Senescence is defined as a 
state of permanent growth arrest which acts a barrier against cancer formation (reviewed 
in (94, 131)). Senescence is characterized by limited cellular proliferation, an increase 
activity of senescence-associated β-galactosidase (132) and the appearance of 
senescence-associated heterochromatin foci (reviewed in (133, 134)). p16Ink4a deficient 
melanocytes demonstrated impaired senescence which is different then p16Ink4a-deficient 
MEFs which senesce normally (135, 136), suggesting p16INK4a -Cdk4-Rb pathway is 
required for escaping senescence in melanocytes.  To elucidate the relative roles of 
p16Ink4a and Arf in melanocytes senescence, Ink4a/Arf deficient mouse melanocytes were 
tranduced with either p16Ink4a or Arf through retroviral vectors (129).  Ink4a/Arf deficient 
mouse melanocytes with p16Ink4a expression showed growth arrest, an increase in 
pigmentation and cell size and increase in senescence-associated β-galactosidase, while 
expression of Arf showed an increase in cell apoptosis and no increase in size or 
senescence-associated β-galactosidase.  Moreover, Ink4a/Arf wildtype mouse 
melanocytes commonly delete p16Ink4a while retaining normal Arf function (129).  These 
findings in mouse melanocytes further support the powerful role of p16Ink4a in 
suppressing melanocytes transformation. 
To investigate the role of p16INK4a, human melanocytes deficient for p16INK4a 
were evaluated for ablation of senescence.  p16INK4a deficient human melanocytes 
showed an increase in cell death; however when cultured with keratinocytes or feeder 
layers of cells, p16INK4a -deficient melanocytes rapidly proliferated and had an extended 
life span, suggesting deletion of p16INK4a is critical for human melanocytes proliferation 
(137).  Finally, using p16INK4a -deficient human melanoma cell lines, wild-type p16INK4a  
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Induction of senescence in melanocytes.  Numerous stimuli have been reported to 
induce senescence in melanocytes: UV light, oxygen radicals, ionizing radiation, 
chemotherapeutic agents, telomere dysfunction, and introduction into cell culture, loss 
of regulator proteins such as BMI-1 and oncogene activation.  In response to stimuli, 
cells increase proteins such as p16INK4a to halt the cell cycle and cell proliferation as a 
safe-guard against malignant transformation. 
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was introduced into these cells and measured for senescence.  As expected p16INK4a 
induced senescence in these cells; however, when these cells were introduced with 
p16INK4a variants which are found in familial melanoma kindreds, R24P and A36P, the 
cells failed to senesce and continued to proliferate (138).  This suggests that p16INK4a is 
an important growth inhibitor in melanocytes and mutations that target p16INK4a ablate its 
ability to promote senescence in melanocytes. 
To establish the roles of p16INK4a and ARF in cancer development, mice lacking 
p16Ink4a while retaining Arf were generated.  p16Ink4a -/- mice developed normally, 
suggesting that p16Ink4a function was to limit aberrant cell proliferation (135, 136).  To 
assess the anti-cancer function of p16Ink4a, p16Ink4a deficient mice were monitored for 
spontaneous tumor growth.  At 28-58 weeks, 10 out 39 p16Ink4a -deficient mice had 
developed tumors, which is significant when compared to wild-type control mice.  
p16Ink4a -deficient mice developed a range of tumor types including: soft-tissue sarcoma, 
splenic lymphoma and melanoma.  Moreover, p16Ink4a-deficient mice had an increase rate 
of tumor development after exposed to certain carcinogens such DMBA, when compared 
to treated wild-type mice.  These data support that p16Ink4a is an important regulator of 
the cell cycle and tumor formation. 
Cancer is defined as uncontrolled cell proliferation while aging is defined as the 
decline in the replicative potential of cells, for this reason p16INK4a has been studied in 
cancer as well as in aging (94).  Senescence and p16INK4a has recently been shown to be 
involved in mammalian aging.  Expression studies of young vs. aged tissues have 
demonstrated an increase in p16Ink4a expression with aging in many tissues of both 
rodents and humans (139-141).  Recent studies using p16Ink4a deficient mice and p16Ink4a 
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over-expressing mice have shown p16Ink4a has a causal role in the age-induced decline of 
function in certain tissues: the hematopoietic stem cells (HSCs), neural stem cells, and 
pancreatic islets (142-144).  The effects of p16Ink4a in these tissues were Cdk4/6 
dependent and showed that deletion of p16Ink4a increased the capability of these tissues to 
renew in old mice.  These findings not only suggest that p16Ink4a could be used as a 
physiological maker of aging as opposed to a chronological age, but that p16Ink4a has a 
causal role in aging in specific Cdk4/6 dependent tissues. 
While p16INK4a and ARF are mostly regulated in similar fashions, there are known 
specific positive regulators of p16INK4a. Numerous stimuli have been reported to induce 
p16INK4a expression: UV light, oxygen radicals, ionizing radiation, chemotherapeutic 
agents and telomere dysfunction (Figure 3) (113, 145).  Importantly, p16INK4a expression 
has been shown to increase in response to MAPK activation, which is functionally 
relevant in melanoma where many melanomas that harbor activating N-RAS or B-RAF 
mutations selectively delete the INK4a/ARF locus (146, 147).   
On the other hand, p16INK4a and ARF are repressed by common mechanism.  The 
T-box proteins and the polycomb group (PcG) genes (ex. BMI-1) have all been shown to 
down-regulated the expression of three genes: p16INK4a, ARF and p15INK4b (148-150).  
BMI-1 is a member of the polycomb group genes that are involved in regulating gene 
expression by maintaining gene silencing through chromatin remodifications (151, 152).  
One of the main targets of BMI-1 regulation is the INK4a/ARF locus (reviewed in (94)).  
Mice deficient for Bmi-1 showed a failure of the hematopoietic stem cells to self renew 
which is partially rescued by Ink4a/Arf deficiency (149, 153-155).  Moreover, Bmi-1 
directly represses the Ink4a/Arf locus, specifically p16Ink4a, through direct association 
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with the locus and is dependent on the EZH2 containing polycomb repressive complex 2 
(PCR2) (156, 157).  However, this repressive interaction occurs in cells with intact 
p16Ink4a-Cdk4-Rb signaling, cells lacking Rb protein family members had disrupted BMI-
1 directed repression of the INK4a/ARF locus.  Moreover, under stress and senescence 
EZH2 levels decreased as well as the H327Me3 (repressive methylation mark), resulting 
in the displacement of Bmi-1 and activation of p16Ink4a transcription (156, 157).  These 
results suggest how the INK4a/ARF locus and polycomb group genes interact in 
regulating senescence and cancer. 
ARF 
 The final major component of the melanoma susceptibility locus 
INK4a/ARF/INK4b is ARF.  The primary role of ARF is to bind to and inhibit MDM2, an 
E3 ubiquitin ligase.  Inhibition of MDM2, prevents the polyubiquitination and subsequent 
polysomal mediated degradation of p53.  Stabilization of p53 results in activation of p53 
target genes which involved in cell cycle arrest, cellular senescence or cell (158-160). 
While the ARF tumor suppressor locus is strongly associated with p53 signaling, there 
are p53-independent mechanisms of ARF that have been identified (reviewed in (161)).  
Murine studies have demonstrated the importance of ARF in tumor suppression is 
independent of p16INK4a and although most work elucidating the role of ARF is mediated 
through p53 signaling, evidence has suggested that ARF can act independently of p53.  
For example, Arf over-expression in p53 null murine embryonic fibroblasts (MEFs) has 
been shown to induce cell cycle arrest and cause apoptosis, suggesting Arf has other 
targets than p53 to induce tumor suppression (162).  Recently studies that evaluated Arf 
tumor suppressor activity in melanoma, suggested that Arf functions independently of 
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p53 to induce melanocyte senescence and prevent tumor formation (163).  Re-expression 
of Arf in Ink4a/Arf - /- mouse melanocytes with or without p53 potently induced 
senescence in these cells, suggesting that the Arf-p53 pathway was not necessary for Arf 
to suppress melanocytic transformation.  Arf’s p53-dependent and p53-independent 
tumor suppressor mechanisms have pushed it to the forefront of cancer and senescence 
research. 
 As previously discussed the role of p16INK4a in melanoma is irrefutable; however 
it is much less clear how ARF functions in melanoma.  While germline mutations of the 
INK4a/ARF locus found in the majority of familial melanoma kindreds seem to target the 
function of p16INK4a or target exon 1α, ARF-specific mutations and mutations targeting 
exon 1β are rare.   Nevertheless, a majority of these germline mutations affect exon 2 
which is shared between p16INK4a and ARF implicating ARF as a tumor suppressor in 
melanoma.  Approximately 20% to 40% of mutations found the INK4a/ARF locus in 
somatic cancers affect the amino acid sequence of both products (164).  Studies have 
demonstrated that mutations in ARF and in exon 1β, which are associated with melanoma 
familial kindreds have diminished ability to activate the p53 pathway and were unable to 
arrest the growth of p53 expressing melanoma cell lines (165-167).  In colorectal cancer, 
ARF expression was down regulated through hypermethylation, suggesting targeting 
ARF is a mechanism to escacpe tumor suppression (168, 169).   
 While ARF’s role in human cancer is either underestimated or functionally not 
important, in mice Arf is a potent tumor suppressor.  Mice deficient for Arf but 
expressing functional p16Ink4a develop a wide sprecturm of tumors with a short latency 
(170, 171).  Moreover, ARF-null mouse embryonic fibroblasts do not senesce and are 
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transformed by oncogenic H-Ras expression.  These data when compared to loss of 
p16Ink4a suggest Arf deficiency is more tumorigenic in mice.  The important role of Arf in 
murine tumor suppression is strikingly different in humans, where selective inactivation 
of ARF has only been reported in a small number of cancers, this discrepency may be 
attributed to the differences in species or the somatic nature of mutations found in human 
cancers. 
ARF interacts with many other proteins than MDM2 including MYC, E2F1, 
DMP-1 suggesting ARF regulation is not limited to the ARF-p53 pathway.  The E2F 
transcription factors have shown to directly regulate ARF expression; E2F3b binds and 
represses ARF express while E2F1 promotes ARF expression (160, 172) .  E2F 
transcription factors are involved in the S phase of the cell cycle and their interaction 
with ARF directly links ARF to cell cycle control independently of p53 signaling.  In 
addition to the E2F transcription factors, ARF has been shown to interact and attenuate c-
Myc signaling through relocalization of c-Myc from the nucleoplasm to the nucleolus, 
suggesting that c-Myc is a bona fide target of ARF in tumor suppression (173).  As 
previously discussed and described in Figure 4, ARF along with p16INK4a are directly 
repressed by several groups of proteins such as T-box proteins and the polycomb group 
genes.  
E. p53 
 p53 is recognized as the principal guardian of human genome due to its ability o 
respond to DNA damage and protect the cell from aberrantly proliferating (reviewed in 
(161, 174)).  Normally, p53 has a short half life and is expressed at low levels.  Upon 
DNA-damage through a variety of mechanism, such as hypoxia, oncogenic stress, UV-
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irradiation, p53 is stabilized and subsequently can activate downstream effectors which 
either can halt the cell cycle, cause cellular apoptosis or cellular senescence (Figure 5) 
(175-178).  p53 is regulated by the human of double minute 2 (HDM2) or in mice 
MDM2, which targets p53 to proteosome-mediated degradation through ubiquitination.  
ARF, a regulator of MDM2, is a critical inhibitor of MDM2 which allows p53 
stabilization.  When p53 function is abrogated it leads to aberrant proliferation of cells 
with genetic alterations and genomic instability, attenuates cellular apoptosis and 
compromises cell cycle arrest resulting in malignant progression (179-181).  p53 
deficient mice develop normally but have a higher incidence of spontaneous cancer 
development (182).   Due to its important role in maintaining the integrity of genome, 
inactivating somatic p53 mutations are found in many human cancers; however its role in 
human melanoma has been inconsistent. 
 Somatic mutations in p53 have been reported in approximately 50% of all human 
cancers, making it the single most frequent event in human cancer (183-187).  In 
melanoma, due to the lack of ARF function, p53 status has been called into question with 
many studies demonstrating a lack of p53 mutations in primary melanomas to metastasis.  
However, several studies have reported mutations in p53 ranging from 11% to 29% in 
melanomas (188-190).  Most mutations in p53 affect known “hot spots regions (191);” 
however  mutations found in melanoma affect C:G base pairing by substitution with  T:A 
pairs, a common mutation associated with UV-induced damage.  This suggests that p53 
could be a main target of UV-induced damage in melanocytes (60, 190, 192, 193).  
Moreover, single nucleotide polymorphisms have been identified in the TP53 gene and  
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 Figure 4 
 
 
 
Regulation of the INK4a/ARF/INK4b tumor suppressor locus.  There are many known positive 
and negative regulators of the INK4a/ARF/INK4b locus.  Activators include many factors that 
promote DNA damage or aberrant cell proliferation, which stimulates the INK4a/ARF/INK4b 
locus as an anti-cancer response.  Negative regulators such as BMI-1 and Tbx2/3 are known to 
associate with the locus and repress its activation. 
Figure 5 
                                                           
 
 
Activation of the p53 pathway.  p53 is known as the gate keeper of the human genome; 
therefore it responds to many deleterious stimuli that induce DNA damage or cause aberrant cell 
growth and proliferation.  Activation of p53 involves MDM2 inhibition along with binding of 
co-factors and post-translation modifications.  p53 stimulates many anti-cancer cell processes 
such as cell cycle arrest, senescence, cell apoptosis and maintaining genomic integrity. 
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have been associated with the development of cutaneous melanoma (194).  One study 
suggested that single nucleotide polymorphism (SNP) Arg72Pro of the p53 gene 
associated with an increase risk for developing melanoma (195).  While the data for 
p53’s involvement in the pathogenesis of melanoma is controversial, the role ARF-p53 
pathway is undeniable with the majority of melanomas altering either ARF or p53. 
F.  RAS signaling pathways 
The Ras superfamily of small guanine triphosphates (GTPases) consists of 
approximately 150 members (196).  There are five major families: Ras, Rho, Rab, Ran 
and Arf  (Table 4) (197).  All small GTPases share common biochemical mechanisms 
and act as a molecular switch for a diverse range of cellular processes which include cell 
proliferation, cell survival, cell motility, cell migration, endocytosis, intracellular 
trafficking, regulation f the actin cytoskeleton and gene expression (reviewed in (196)). 
Ras GTPase signaling begins with extracellular stimuli that activates receptor tyrosine 
kinases, such as the epidermal growth factor (EGFR) which is a main stimulator of Ras 
activation.  In addition, small GTPases activation fluctuates between a GDP-GTP bound 
state, which is controlled by two main classes of regulatory proteins: guanine nucleotide 
exchange factors (GEFs) and GTPase activating proteins (GAPs).   GEFs promote the 
active state which is GTP bound (198), whereas GAPs accelerate the slow intrinsic GTP 
hydrolysis of Ras to induce inactive state which is GDP bound state (199, 200).There are 
three main GEFs that regulate Ras function in vivo which include: Sos, Ras-GRF and 
RasGRP.  All three have different mechanisms of regulation.  Upon receptor stimulation, 
Sos forms a complex with Grb2, an adaptor protein, which is recruited to the membrane 
where it is positioned proximally to the membrane-associated Ras (201).  Ras-GRF  
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 Figure 6 
 
 
  
 
 
 
Regulation of RAS GTPases.  A) Ras GTPase fluctuates between an active state (GTP-
bound) and an inactivate state (GDP-bound) which is controlled by two classes of regulatory 
proteins: GEFs (guanine nucleotide exchange factors) which stimulate RAS activation and 
GAPs (GTPase activating proteins) which accelerate the slow intrinsic GTP hydrolysis of 
Ras.  B) Lipid modification to the CAAX domain of Ras is another form of regulation of Ras.  
A farensyl group is added to the cysteine residue by farnesyltransferases, which are potently 
inhibited by FTIs (farensyltransferaseihibitors).  Proteolytic cleavage of the AAX sequence is 
catalyzed by Rce (Ras-converting enzyme-1).  Finally, carboxymethylation of the terminal 
cysteine residue is catalyzed by Icmt (isoprenylcysteine carboxymethyltransferase-1 enzyme.  
Alternative lipid modifications occur N/K-Ras occur in the presence of FTIs and involve 
gernylgernyltransferases. 
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activation of Ras is associated with Ca2+ influx.  Finally, Ras- GRP’s regulation of Ras is 
influenced by diacylglycerol (DAG) and phorbol ester.   
While it is understood that Ras-GAPs stimulate the intrinsic GTP hydrolysis of 
Ras, little information is known about the mechanism of this regulation (Figure 6a).  
Members of Ras GTPase family include p120RasGAP, Neurofibromin 1 (NF1) (202), 
GAP1iP4BP and Gap1m.  There activity is thought to be constitutive and acts as a 
secondary role as a signal mediator of Ras signaling (reviewed in (199)). 
While GEFs and GAPs are proteins that regulate Ras signaling, Ras can be 
regulation through post-translation modification by lipids (203-205).  The C-terminus of 
Ras terminates with a CAAX domain (C=cys, A=aliphatic, X=any amino acid), which is 
recognized by both farensyltransferases and gernylgernyltransferases which catalyze the 
addition of either farnesyl or gernyl isoprenoids to the CAAX domain.  This modification 
to the CAAX domain influences the subcellular location and the protein interaction 
(Figure 6b). 
Ras 
Ras sarcoma proteins are the founding members of Ras GTPase family, which 
consists of 36 members.  Other members with oncogenic potential like Ras are Rap, R-
Ras, Ral and Rheb, whereas members such as Rerg and Noey2 are known to have tumor 
suppressor activity.  Ras GTPases are usually anchored into the inner face of the cell 
membrane where they are recognized as signaling nodes which direct numerous signaling 
networks and cell processes, such as cell proliferation, cell growth, and cell survival (204, 
206-208). 
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There are three human Ras proteins: H-Ras (Harvey sarcoma virus), N-Ras 
(neuroblastoma) and K-Ras4a/4b (Kirsten sarcoma virus) (reviewed in (209, 210)).    All 
three proteins share a conserved G domain, which acts as the “switch”, as it binds to GTP 
and other protein effectors; however the C-terminus of all three proteins contains a hyper-
variable region (HVR) which consists of a linker domain and a lipid anchor.  The lipid 
anchor, where the CAAX domain is located,  is responsible for membrane association of 
the different isoforms of Ras.  Depending on the Ras isoform the CAAX domain 
undergoes specific post translational modifications that promote membrane binding.  H-
Ras and K-Ras are both highly associated with the cell surface, whereas N-Ras primarily 
associates with endomembrane components (211).   
While they are highly homologous with similarities in biochemical properties and 
structure they have been shown to function differently in various tissues (reviewed in 
(212, 213).  Reasons for their differences in function include: 1. Ras isoforms respond 
differently to stimuli; therefore they are not functional redundant (214), 2. Different Ras 
isoforms are targets in different cancers (215), 3. Ras isoforms can activate specific 
downstream targets (216, 217), 4.  Ras isoform localize differently in cells and have 
different abundances in certain tissues (218) 5. Mouse genetic studies of Ras isoforms 
have shown that Ras isoforms have different roles in development.  Genetic studies using 
knock out strategies, have shown that H- Ras and N-Ras single and double knockouts and 
K-Ras4a knockouts are developmentally normal; whereas K-Ras4b-/- knockouts are 
embryonic lethal, suggesting that there are different roles for the Ras isoforms and K-
Ras4b is required for embyrogenesis (219-223).  Further analysis using a knock-in 
strategy to replace K-Ras with H-Ras demonstrated that mice with a H-Ras gene under a 
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K-Ras promoter were normal, indicated that K-Ras4b was required in a specific 
expression pattern and not necessary for activation a specific signaling network (224).  
Furthermore, low level ectopic expression of different Ras isoforms stimulated activation 
of different pathways.  For example, expression of H-Ras induced potent activation of the 
PI3 lipid kinase pathway, while expression of K-Ras activated downstream effectors Raf 
and Ral (225).  While there are many similarities of the Ras isoforms, research is being 
conducted to elucidate specific roles of each isoform in signaling networks and 
expression patterns. 
The best characterized signaling cascade of Ras is the RAS-RAF-MEK-ERK 
pathway.  Signaling begins when an extracellular stimuli, such as the epidermal growth 
factor, binds to a receptor tyrosine kinase found on the cell membranes, such as the 
epidermal growth factor receptor.  This interaction activates Ras and it becomes GTP-
bound.  Acitvated Ras recruits Raf, a serine/threonine kinase, to the cell membrane where 
it undergoes several activating phosphorylation events (226-228).  Activated Raf 
phosphorylates the downstream targets MEK1 and MEK2, dual specificity kinases, which 
subsequently phosphorylates ERK1 and ERK2 mitogen activate protein kinases 
(MAPKs).  ERK1/2 translocate into the nucleus where they regulate transcription of 
thousands of genes involved in a myriad of cell processes through modulation of 
transcription factors such as the E26 transcription factor protein (Ets) family.   
While, Raf is a main target of Ras there are other downstream effectors of Ras, 
which include RalA/RalB, Rab5, Rac, Rho, Rap and PI3K lipid kinases (Figure 7).  RalA 
and RalB have recently been shown to be involved in anchorage independent growth of 
cancer cells and cell survival, respectively.  Both RalA and RalB are linked to Ras  
  36 
 
 
Table 4 Ras superfamily of GTPases and their Function 
GTPase Family Function 
Ras Family Signaling  nodes to diverse extracellular 
stimuli, regulates gene expression, cellular 
proliferation, differentiation, survival 
 
Rho Family 
Regulates cytoskeleton, actin organization, 
cell cycle progression, gene expression, 
cell polarity 
Rab Family Regulates intracellular vesicular transport, 
trafficking proteins between the endocytic 
and secretory pathways 
Ran Family Regulates nucleocytoplasmic transport of 
both RNA and proteins 
Arf Family Regulation of vesicular transport 
 
 
Table 5 Ras mutations in Human Cancer 
Cancer N-Ras H-Ras K-Ras 
Biliary Tract 1% 0% 32% 
Breast 1% 1% 5% 
Hematopoietic/lymphoid 
tissue 
12% 0% 5% 
Lung 1% 0% 17% 
Pancreas 2% 0% 60% 
Salivary gland 0% 17% 3% 
Skin 18% 5% 3% 
Urinary tract 3% 12% 4% 
Data compiled from the Catalogue of Somatic Mutations in Cancer (COSMIC) 
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activation through RalGEFs and subsequently deactivated through Ral GTPases (229-
231).  Signaling pathway through RalA and RalB activation is involved several processes 
which include: endocytosis, exocytosis, actin organization and gene expression (232).  
Rab5 is a member of the Rab family of GTPases which is the largest branch of the Ras 
superfamily consisting of approximately 63 members.  It is regulated through RIN1, a 
Ras effector that functions as a GEF (233).  Rab5 activation is associated with 
intracellular vesicular trafficking (234).  The Ras-Rac interaction is connected through 
the Rac-specifc GEF activity of Tiam1 (235).  Activation of Rac is implicated in several 
different cellular functions such as gene expression, cell cycle progression, actin 
organization and endocytosis.  Both Rho an Rap have been linked to Ras activation 
through the G-protein coupled receptor activation of PLCε or the lipase activity of PLCε 
(236, 237).  Rho and Rap are proteins involved in the cell cytoskeleton and cell adhesion 
(reviewed in (238)).  Finally, a common oncogenic event is activation of the PI3K lipid 
kinase pathwaythrough Ras activation, which leads to up-regulation of AKT and increase 
cell survival for tumor cells.  All of these Ras activated pathways are implicated in 
mechanisms that lead to the different phases of tumor progression: transformation, 
invasion and metastasis. 
Ras signaling cascades are involved in many processes of the cell, which makes it 
an attractive target for mutagenesis during tumor progression.  Mutations in Ras are 
found in approximately 30% of human cancers (215).  Mutations in K-Ras are found in 
90% to 100% of pancreatic cancers and are found in 50% of colon cancers, making K-
Ras the most mutated Ras isoform in cancer (214).  H-Ras mutations are found primarily 
in bladder cancer (239), while mutations in N-Ras are found in both lymphoid  
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RAS effector signaling pathways.  There are many downstream effectors of Ras, which 
include Raf, RalA/RalB, Rab5, Rac, Rho, Rap and PI3K lipid kinases.  Activation of these 
effectors stimulates a myriad of cellular processes which include:  cell proliferation, gene 
expression, cell differentiation, cell growth, cell survival, cell apoptosis, intracellular 
vesicular trafficking, endo and exocytosis, actin organization, regulation of the cytoskeleton 
and cell adhesions. 
Figure 7 
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malignancies (240-242) and melanoma (reviewed in table 5) (56).  Common point 
mutations are found in either exon 12, 13, or 61 (243), which all interfere with GAPs 
ability to enhance the intrinsic GTP hydrolysis of Ras, consequently leaving Ras in a 
constitutively active (GTP bound) state (244) .  Expression of oncogenic Ras isoforms in 
NIH3T3 fibroblasts transformed the cells; however it was shown that neither oncogenic 
N-Ras nor K-Ras were as potent as expression of H-Ras, suggesting H-Ras’ ability to 
interact with downstream effectors(245).   
Activating mutations of N-Ras are observed in approximately 20% of melanomas.  
They are associated with nodular melanomas and melanomas found in sun exposed areas; 
however they are rarely found in dysplastic nevi, common precursors to melanoma(246).  
In melanoma, N-Ras mutations exclusively target exon 61, with approximately 90% of 
N-Ras mutations found in exon 61 (70). H-Ras and K-Ras mutations are rarely found in 
melanoma; however H-Ras mutations are associated with Spitz nevi(247).  In vitro 
studies using INK4a/ARF deficient melanocytes demonstrated that over-expression of 
oncogenic N-RasG12V transformed melanocytes with greater efficiently and were easily 
transplantable in xenograft mice than melanocytes which overexpressed either oncogenic 
H-Ras or K-Ras, suggesting N-Ras is the more oncogenic Ras isoform in melanocytes 
transformation (248).  Lastly, in vivo studies using a doxycyclin inducible  H-Ras allele, 
under the tyrosinase promoter, demonstrated that oncogenic Ras signaling was essential 
for initiation and maintenance of melanomas in mice (249).  As discussed earlier there 
are many different Ras signaling pathways, in melanoma the Ras signaling pathway that 
is usually activated in melanoma is the RAS-RAF-MEK-ERK pathway, which has been 
shown to be involved in the progression of melanoma.  Therefore this pathway has been 
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shown to have other perturbations which can activated the pathway, such as activating 
mutations in B-Raf, the direct downstream target of Ras. 
G. B-RAF Activation 
 Raf proteins are cytosolic serine/threonine kinases which are the main targets of 
Ras downstream signaling (250-253).  Raf activation has been involved in many cellular 
functions such as development, cell cycle regulation, cell proliferation, cell 
differentiation, cell survival and cell apoptosis (reviewed in (254, 255)).  There are three 
main isoforms of Raf: A-Raf, B-Raf and C-Raf.  They all share three conserved regions 
which include: 1) the Ras binding domain (RBD), the cysteine rich domain (CRD) which 
contains a high amount of serine and threonine residues which are phosphorylated and 
activating Raf, 3) the kinase domain.  While they share similar regions, the Raf isoforms 
have essential and non-overlapping function in embryogenesis and organ development 
(254).  A-Raf knockout mice are born alive, but have both neurological and intestinal 
abnormalities, while both the B-Raf and C-Raf knockout mice are embryonic lethal (254, 
256-258).  Moreover, it has been shown that different Ras isoforms can activate different 
Raf isoforms to varying intensities, for example K-Ras has been shown to activate C-Raf 
with greater intensity than either N-Ras or H-Ras.  These findings not only support the 
idea that different Raf isoforms have independent functions, but they are also regulated 
by Ras in varying degrees. 
The main function of Raf kinases has been to activate MEK and ERK (226, 259, 
260).  Phosphorylation of these downstream targets leads to translocation of ERK into the 
nucleus where it associates with transcription factors such Ets1 (261).  Until recently, 
ERK-regulated gene expression was mostly unknown with target genes being involved in 
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the cell cycle, Cyclin D1 (262) and p27Kip1 (263); however gene expression analysis have 
identified many novel targets associated with ERK activation in melanoma cell lines 
which include: TWIST1, IL8, HIF1α (264).  Moreover, it has been shown that expression 
of ERK is associated with increase expression of matrix metalloproteniases (MMPs), 
which are involved with invasion and metastasis (265).   
While, Raf kinases primarily link Ras activation to MEK/ERK signaling there are 
MEK-independent pathways that have been identified through experiments that either 
inhibit MEK using pharmacological inhibitors or by directly down regulated B-Raf using 
siRNA specific for B-Raf (250, 266) .  New targets that have come out these screens 
included targets involved in cell death (ASK-1 (267), MST-2(268)), cell cycle (RB(269), 
Cdc25(270)), cell survival (NFκB (271), BAD (272)) and cytoskeleton organization 
(vimentin, keratin 8).   
Raf was first isolated in 1983 as a potential oncogene, since then many studies 
have looked at the roles of Raf in cancer (253).  While the focus has been the role of C-
Raf in cancer, recently the direction has slightly shifted to B-Raf with identification of B-
Raf specific mutations in various human cancers (273).  Mutations in B-Raf have been 
indentified in 70% of melanomas, 30% of thyroid cancers, and 15% of colon cancers 
(274-276).  Approximately 90% of the mutations found in B-Raf affected the kinase 
domain with a single base substitution V600E engendering a constitutively active kinase 
(15).   Furthermore, mutations in Ras and Raf are almost always mutually exclusive, as 
seen in melanoma and recently in colon cancer suggesting that one activating mutation in 
the MAPK kinase is sufficient for transformation (277-279).   
  42 
 
The high incidence of B-Raf and N-Ras mutations in melanoma has established 
that the RAS/RAF/MEK/ERK pathway is a signaling cascade that is a hallmark of 
cutaneous melanoma (15, 63).  B-Raf mutations were found in 82% of nevi, 66% of 
primary melanomas, and 40-68% of metastases (15, 63, 280, 281) .  Increased B-Raf 
expression has been associated with cell proliferation, tumor invasion and metastasis 
(282).  In vitro experiments using MEK inhibitors or B-Raf siRNA has demonstrated that 
B-Raf signaling is important in growth and proliferation of melanoma cell lines (283-
285).  Moreover, in vivo experiments employing melanoma xenograft models have 
shown that oncogenic B-Raf activity is required for both the initiation and maintenance 
of melanomas in vivo (286).  
The phenomenon that nevi frequently carry B-RafV600E mutations has suggested 
that oncogene-induced senescence happens in vivo (287).  In vitro experiments using 
expression of oncogenic BRAFV600E induced SA-β-gal positive growth arrest in cells.  In 
vivo analysis of nevi, demonstrated that nevi stained positively for SA-β-gal and showed 
a decrease of Ki67 staining (16). These findings have established that N-Ras and B-Raf 
mutations are initiating mutations in melanocytes transformation.    However, nevi 
represent an unproliferative and physiological protective state indicating that mutations in 
the RAS-RAF pathway may be involved in the initiation and maintenance of melanomas 
but acquisition of additional mutations such as the loss of p16INK4a, are necessary for 
melanomas to progress to a more invasive phenotype. 
H. Summary: The Complexity of Melanoma 
 Here we discussed the many factors that influence the development and 
progression of melanoma.  Melanoma is a complex disease with both genetic and 
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environmental factors, with loss of p16INK4a associating with familial melanoma kindreds 
and UV exposure have a direct effect on melanoma development.  Filtering out individual 
components of the pathogenesis of melanoma is the next step in developing efficient 
therapies for more progressive forms of melanoma.  Recently, mouse models of 
melanoma have elucidated some of the pathways in melanomagenesis and have generated 
a better understanding of the pathogenetics involved in melanoma development.   
Detailed analysis of these mouse models along with generation of improved mouse 
models of melanoma will provide the opportunities to develop effective therapies for 
melanoma in the future. 
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Chapter 
II.  Genetically Engineered Mouse Models of Melanoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Genetically Engineered Mouse Models 
 Cancer is a heterogeneous and complex disease consisting of many different types 
which are defined by specific genetic lesions, environmental risk factors, 
histopathological characteristics and many other factors.  While, both in vitro and in vivo 
studies have defined some of the factors involved in the complexity of human cancers, 
genetically engineered mouse models (GEMMs) have become the key model to elucidate 
the intricate pathways involved in tumorigenesis.  In vivo manipulation of gene 
expression not only affects the gene itself but also how mutanted genes interact with the 
microenvironment, immune system, and the stroma.  Therefore, mouse models of cancer 
recapitulate what occurs in humans and can phenocopy the human disease.  Over the last 
couple of decades several strategies to develop manipulate gene expression in the mouse 
have been developed (reviewed in (288)).  Here, we will discuss the different methods 
and how they regulate gene expression (reviewed in Figure 8). 
Random integration and homologous recombination 
 One of the first and simplest methods to study gene function and expression in a 
mouse is exogenous expression of a protein in all or some tissues (reviewed in (289)).  
For this method, a foreign piece of DNA is introduced into the mouse genome, which 
usually includes the gene of interest (GOI), a strong promoter, an enhancer to induce 
gene expression and vector DNA, which allows for the construct to be inserted into the 
mouse genome.  Through pronuclear injection or lentiviral infection of mouse zygotes, 
the transgene can be inserted into the mouse genome; however insertion is random and is 
able to disrupt critical gene loci and can also integrate into the genome with more than 
one copy, varying from one to several hundred.  Many of the first transgenic mice were 
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used to study over-expression of non-mutated proteins, expression of dominant negative 
forms of proteins or expression of fluorescent tagged proteins.   
 Due to the random integration of the first transgenic mouse lines, new ways to 
target gene expression were necessary to evaluate specific gene function in the mouse.  
Homologous recombination in mammalian cells was first adapted by Smithies in 1985 
(290) and has been used to model any deletion, point mutation, inversion or translocation 
in the mouse.  The DNA construct, which is to be inserted into the mouse genome, 
contains several kilobases of DNA which is homologous to the mouse genome in order to 
direct recombination.  The vectors also usually carries certain modifications, such as drug 
resistant to neomycin which allows selection of the targeting ES cells in a large ES 
population because homologues recombination at the locus of interest in mammalian 
cells does not occur at a high rate.  There are several ways to use homologous 
recombination to manipulate gene expression: knockins or knockouts (291).  A knockin 
mouse is generated by replacing the targeted locus with the DNA construct which for 
example can harbor a point mutation.  However, knockin mice are used to study gene 
expression; therefore, knockout mice have been generated to evaluate the function of 
gene through ablation of the gene function.  Homologous recombination allows for the 
removal of coding sequences (exons) from a gene, which can result in a non-functional 
protein, through mutation, truncated protein or complete absence of functional protein.  
The phenotypes of these models can be very complex because all the tissues in the mouse 
harbor the transgene and can be affected; therefore for the phenotype of knockout mouse 
models can range from no signs of alternations in function to embryonic lethality. 
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Figure 8 
Generation of Mouse Models:  A) Random integration of gene of interest into the mouse 
genome.  B)  Homologous recombination to generate a knockout allele by removing exons 
2, 3 and 4.  Homologous recombination uses several kilobases of DNA which is 
homologous to the mouse genome in order to direct recombination.  C)  The use of RNAi to 
downregulate gene expression through homologous recombination into the mouse genome.  
D)  The tet-inducible system uses an rtTA receptor protein under a cell specific promoter to 
turn on or off gene expression. E) The CRE recombinase system utilizes different 
recombinases to manipulate gene expression between specific recognition sites, has loxP 
sites.  
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Regulatable Gene Expression 
 Knockin and knockout mouse models inherently do not reflect the somatic 
mutations often found in human cancers and genes that are essential for mouse 
development viability and fertility can cause lethality in these mice.  Conditional gene 
expression has been developed to spatially and temporally regulated gene expression; 
therefore, investigators can study their gene of interest in a specific cell type and at a 
specific time during development or in adult mice.  Conditional gene expression defines 
gene function in development, physiological and behavior.  There have been several 
regulatable mouse models developed: the tet-inducible system, the CRE-loxP system and 
the FLP/FLT system.  The tet-inducible system requires administration of tetracycline to 
regulate gene expression, whereas the CRE-loxP and FLP/FLT systems use different 
recombinases to manipulate gene function 
 The tet-inducible system involves two different constructs to be integrated into 
the mouse genome (reviewed in (292)).  The first construct encodes a tet receptor protein 
(rtTA), which is controlled under either a non-tissue specific promoter or developmental 
regulated tissue specific promoter and enhancer.  The second construct consists of tet 
operator (tetO) sequences which is targeted to the promoter linked to the gene of interest.  
The rtTA has very high binding affinity for the tetO sequences.  Overall, gene expression 
is either repressed or induced by administration of tetracycline or analogues of 
tetracycline, such as doxycyclin (293, 294).  The first strategy for the Tet inducible 
system was designed to turn off expression; therefore without tetracycline present the 
rtTA binds to the tetO sequences and activates transcription.  After administration of 
tetracycline, tetracycline or analogous bind to the rtTA receptor protein which 
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subsequently can no longer bind to the tetO sequences, which halts gene expression.  The 
second strategy for the Tet-inducible system is similar to the first, however the rtTA 
receptor protein is mutated and can no longer bind to the tetO sequences; therefore gene 
expression will be downregulated.  Introduction of tetracycline into the system, allows 
the mutated rtTA receptor protein to bind to the target sequence and induce gene 
expression within a few hours and gene expression can be regulated in a dose-dependent 
manner, this system is the reverse of the rtTA system. 
 The CRE-loxP and FLT/FLP systems allow for site-directed recombination of 
target sequences to regulate or manipulate gene expression (reviewed in (295, 296)).  The 
CRE-loxP system was adapted from bateriophageP1(297) while the FLP/FLT system was 
adapted from saccharomyces cerevisiae (298).  Cre recombinases are site-specific 
integrases which catalyze recombination between two of its consequence DNA 
recognition sites.  In the CRE-loxP system, the DNA recognition sites are termed loxP 
sites and consist of 34 base pairs.  The orientation or location of the two loxP sites will 
dictate the outcome of recombination which includes: removal of a functional part of the 
gene, inversion of the targeted gene or translocation of a gene.  In order to control the 
expression of CRE, the Cre recombinase can be regulated by several different promoters, 
such as tissue specific promoter, cell specific promoter, developmentally regulated 
promoter, or promoters linked to tet-response elements or ligand bindings sequence (e.g. 
estrogen-response elements) which are responsive to exogenic agent such as tetracycline 
or tamoxifen (299-301).  The CRE-loxP system has been the more popular system to use 
to generate conditional mouse models; however the FLP/FLT system has been shown to 
be useful in targeting gene expression in embryonic stem cells (302). 
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Transgenic RNAi mouse models 
 A new form of gene regulation in mice utilizes RNA interference to ablate gene 
function in vivo (reviewed in (303)).  RNA interference (RNAi) consists of synthesis of 
RNA segments which induce down regulated of gene expression through either inhibition 
of transcription using the RNA-induced silencing (RISC) complex (304) or through 
inhibition of translation (reviewed in (305)).  Transgenic RNAi mouse models use the 
standard constructs to integrate into the mouse genome; however they use shRNAs or 
shRNA-mir-expression constructs to down-regulated gene expression.   One of the 
benefits to using RNAi transgenic mice is that they do not have to be homozygous for the 
DNA construct to induce gene regulation in many of the targeted cells.  While RNAi 
transgenic mice on the rise there are still limitations to their use such as RNAi 
knockdown of genes in never 100% complete, not all cell types are competent to carry 
out RNAi, no other manipulations of a gene can be achieved (e.g. point mutations), 
suggesting that RNAi transgenic mice should be used in complement to the standard 
knockout mouse models. 
B. Current mouse models of melanoma 
 Many mouse models of cancer have been developed that target many different 
pathways thought to be involved in human cancer, in particular melanoma.  The mouse is 
an appropriate model organism to study melanoma in for several reasons, which include: 
1. the mouse genome shares many conserved regions with the human genome, 2. the 
mouse has comparable organs and physiology, 3. extensive analysis of genetic factors can 
be studied in the mouse, 4. generate specific mutants that target candidate genes involved 
in melanoma in the mouse (reviewed in (124, 306)).  However, there are some limitations 
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in studying melanocytes in the mouse, because the structure of the mouse skin differs 
than the structure of human skin.  Mouse melanocytes are predominantly located in the 
dermis and the bulb of the hair follicle; however there are melanocytes located in the 
epidermal-dermal junction which are found in non-hair regions such as pinnae of the ear, 
tail and paws.  Whereas human melanocytes reside in the basal layer of the epidermis; 
therefore, melanomas arising from melanocytes found in the pinnae of the ear, tail and 
paws more closely recapitulate the human form of the disease.  Here we will discuss the 
mouse models of melanoma that have been generated to elucidate the genetic and 
environmental factors involved in the development of melanoma (Table 6). 
 Over the past 15 years many mouse models of melanoma have been generated 
and have discovered valuable information about the genetics of melanoma.  Investigators 
have exploited the tyrosinase family of genes, such as tyrosinase (Tyr), tyrosinase related 
protein 1 (TRP1) and dopachrome tautomerase (DCT), to drive melanocyte-specific 
expression of their genes of interest (307-310).  In addition, tyrosinase distal regulatory 
elements (DRE) have been used to enhance melanocyte-specific expression (311, 312).  
Recently, conditional tyrosinase driven CRE-ERT2 alleles have been generated to regulate 
gene expression in melanocytes through administration of tamoxifen (313, 314).   
Tyr:SV40T-antigen 
 The first mouse model of melanoma was developed in the early 1990’s by 
Beatrice Mintz.  This transgenic mouse model of melanoma harbored expression of the 
SV40 large T-antigen, which disrupts both the Rb and p53 pathways, under the mouse 
tyrosinase promoter (308).  The mice were hyperpigmented and developed both  
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Table 6 Genetically Engineered Mouse Models of Melanoma 
Transgene Knockout/ 
knockin 
Spontaneou
s melanoma 
Induced 
melanoma 
Pigmentation Metastasis 
Tyr:Tag / Yes / Melanotic Yes 
Tyr:HRasV12G p16Ink4a -/-
Arf-/- 
Yes / Amelanotic No 
Tyr:HRasV12G p16Ink4a -/- Yes No (UV) Amelanotic No 
Tyr:HRasV12G Arf -/- Yes Yes (UV) Amelanotic No 
Tyr:HRasV12G p53-/- Yes / Amelanotic No 
Tyr:tet-
HRasV12G
p16Ink4a -/- 
Arf -/- 
Yes Yes (doxy) Amelanotic No 
Tyr:HRasV12G Cdk4R24C No Yes 
(DMBA and 
TPA) 
 No 
Tyr:NRasQ61K p16Ink4a -/-
Arf-/- 
Yes Yes 
(DMBA) 
Melanotic Yes 
Tyr:NRasQ61K 
bcatsta
/ Yes / Melanotic Yes 
HGF/SF +/- p16Ink4a Yes Yes (UV-
neonates 
only) 
Amelanotic Yes 
Data was compiled from primary papers discussed in the preceding chapter. 
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spontaneous and UV-induced melanomas.  However, the majority of melanomas were 
ocular melanomas, a rare form of this disease, and few were cutaneous melanomas. 
Tyr:HRasV12G, Ink4aΔ2/3
 This mouse model of melanoma was developed by Chin et al (312) and exploited 
the use of both the tyrosinase promoter and the upstream enhancer element to drive the 
constitutively activate HRasV12G transgene.  Moreover, these mice were then mated with 
mice deficient for both p16Ink4a and Arf.  Mice expressing the HRasV12G transgene and 
harboring homozygous deletions for both p16Ink4a and Arf, developed cutaneous 
melanomas which were highly vascularized, locally invasive, amelanotic, and nodular.  
However, there was no evidence for metastasis.  Molecular analysis of heterozygous 
tumors for p16Ink4a and Arf showed 100% LOH and 50% deletion of the Ink4b locus, 
suggesting the both Rb and p53 pathways were essential for melanoma development.  To 
dissect the contributions of both pathways in the development of melanoma, 
Tyr:HrasV12G transgenic mice were crossed with mice harboring homozygous deletions 
for either p16Ink4a, Arf or p53.   
Tyr:HRasV12G, p16Ink4a -/- or Arf-/- 
 Mice harboring the Tyr:HrasV12G transgene transgene and homozygous deletion 
for only p16Ink4a developed spontaneous melanomas within 75 weeks and demonstrated 
somatic inactivation of Arf.  Whereas mice harboring the Tyr:HrasV12G transgene and 
homozygous deletion for Arf developed melanomas within 40 weeks and demonstrated 
loss of p16Ink4a.  Both of these models suggest that p16Ink4a and Arf cooperate to suppress 
melanoma in vivo (91).  Further analysis of these models using UVR suggested that 
p16Ink4a -Cdk4-Rbpathway was a main target of UVR-induced damage in melanocytes 
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(315).  Mice harboring the Tyr:HrasV12G transgene and either homozygous deletion for 
p16Ink4a or Arf were treated with UVR and monitored for tumor development.  Only 
deletion of Arf cooperated with UVR in the formation of melanomas, demonstrating an 
overexpression of Cdk6; whereas deletion of p16Ink4a did not cooperate and no melanoma 
formation was observed. 
Tyr:HRasV12G , p53-/- 
 To elucidate p53’s controversial role in melanoma development, Tyr:HrasV12G 
transgene, p53-/- mice were generated and spontaneously developed melanomas, which 
were highly similar to Tyr:HRasV12G, Ink4aΔ2/3 melanomas (316).  These melanomas 
were amelanotic, highly vascularized, locally invasive and did not show evidence of 
metastasis.  Surprisingly p16Ink4a expression was stabilized and expressed in these tumors, 
suggesting other mutations of the p16Ink4a -Cdk4-Rb pathway could have occurred.  
Molecular analysis of the tumors demonstrated an upregulation in Cyclin D1 expression 
along with overexpression of c-Myc. 
Tyr:tet-HRasV12G, Ink4aΔ2/3
 In order to define the role of H-RasV12G in melanoma, an inducible mouse model 
was developed which exploited the use of the tet-on system (249).  In the presence of 
doxycycline, an analogue of tetracycline, H-RasV12G expression was turned on and 
melanomas developed which were nodular, vascular, locally invasive, amelanotic and did 
not metastasize.  Upon removal of doxycycline from the water, H-RasV12G expression 
was downregulated which resulted in both a clinical and histopathological regression of 
both primary and explanted melanomas in a doxycycline dependent manner, suggesting 
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that H-RasV12G was essential for both development and maintenance of melanoma 
formation in vivo. 
Tyr:HRasV12G, CDK4R24C
Human melanomas have been shown to mutate CDK4.  However, mice 
expressing a mutant form of CDK4 R24C, which can no longer be inhibited by p16INK4a, 
along with constitutive active H-RasV12G did not develop melanomas (46).  Exposure to 
mutagens, such as UVR, induced secondary mutations which generated melanoma with a 
high penetrence and short latency.  This model further supports the unequivocal role of 
the p16Ink4a -Cdk4-Rb pathway in melanomagenesis. 
Tyr:NRasQ61K, Ink4aΔ2/3
 While aberrant Ras expression is a molecular signature of melanocytes 
transformation, different Ras isoforms are targets for mutations. In melanoma N-Ras is 
primarily targeted while both H-Ras and K-Ras are rarely mutated; therefore a mouse 
model targeting N-RasQ61K expression on an Ink4aΔ2/3deficient background was generated 
(311).  These mice develope cutaneous melanoma, which are highly pigmented, tend to 
invade the dermis and demonstrate the ability to metastasize to the lymph nodes, lung and 
liver.   
Tyr:NRasQ61K,  bcatsta
 The Wnt-β-catenin signaling pathway is upregulated in 30% of human 
melanomas; therefore a mouse model of melanoma was generated using a stabilized form 
of β-catenin along with a constitutively active N-RasQ61K under the regulation of the 
tyrosinase promoter and DRE to direct melanocytic expression (89).  These mice 
developed highly pigmented and metastatic melanomas, which surprisingly showed a 
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down regulation of p16Ink4a expression.  Further analysis, demonstrated that β-catenin 
directly repressed the expression of p16INK4a and in human melanomas harboring N-
RasQ61K mutations and aberrant expression of the Wnt-β-catenin signaling pathway have 
a low level of p16INK4a expression. 
HGF/SF +/- UV radiation 
 The heptocyte growth factor/scatter factor stimulates melanocyte proliferation and 
mice expressing HGF/SF can develop a variety of tumors which include melanomas.  
UVR is thought to be a main mutagen involved in melanoma development; therefore 
using mouse models to determine how UVR is involved in the pathogenesis of melanoma 
will elucidate the targeted pathways.  Transgenic HGF/SF mice were treated with one 
treatment of UVR as either neonates or as adults.  Interestingly, only UVR treated 
neonates developed melanomas with high penetrence and short latencies, whereas UVR 
treated adult mice showed no signs of melanoma formation.  These findings suggest that 
early exposure to UVR is more efficient at transforming melanocytes than UV exposure 
later in life (317).  Furthermore mice harboring the HGF/SF transgene and homozygous 
deletions for both p16Ink4a and Arf were treated with UVR, which demonstrated that UVR 
could induce melanomas in these mice as well and that abrogating both the p16Ink4a-
Cdk4-Rb and Arf-p53 pathways enhanced melanoma formation (318). 
C. Summary: Applications of mouse models of melanoma 
 To date many of the mouse models of melanoma have not resembled the human 
form of melanoma which is characterized by somatic mutations and its proclivity to 
metastasize.  However  the development of the conditional TyrCREERT2 allele has 
generated new and exciting mouse models of melanoma which exploit the somatic nature 
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of the common mutations found in melanoma (313, 314).  Conditional activation of K-
RasG12DP  along with somatic acute loss of both p16Ink4a and p53 has been shown to 
cooperate in melanoma formation (Monahan unpublished) as well as conditional 
activation of B-RafV600E along with somatic loss of PTEN (72).   These conditional 
models will help decipher how somatic activation and somatic loss of genetic targets in 
melanoma interact with the host microenvironment, immune system, and stroma.  
Conditional mouse models of melanoma will allow a better model to assess the efficacy 
of anti-cancer therapies.   
 While mouse models can be used to determine genetic factors involved in the 
spectrum of human cancer progression, a major focus of mouse models is there utilization 
to develop effective therapies for cancer patients (reviewed in (289, 319)).  However, the 
pharmaceutical industry has a long history with using xenograft models of cancer to 
determine drug efficacy in a variety of human cancers.  Relevant genetically engineered 
mouse models could be potential platforms for discovery of new targets and biomarkers, 
target validation and preclinical trials for any emerging or existing anti-cancer therapy.   
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Chapter  
 III.  Melanoma and the Immune System 
 
 
 
 
 
 
The immune system is a complex network of specialized cells, tissues and organs 
that have evolved to defend our body against foreign invaders.  The regulation of the 
immune system demonstrates a fine balance between normal function, whenthe immune 
system attacks potential harmful pathogens, to lack of function seen in a torrent of 
diseases from allergies to AIDs, and finally to an over-reactive immune system when it 
attacks the body’s normal tissues seen in diseases, such as vitiligo and rheumatoid 
arthritis.  The immune system has been able to develop a system that entails two 
opposing tasks, because it is able to distinguish between self and non-self cell surface 
antigens.  Recognition of non-self cell surface antigen initiates a signaling cascade and 
consequently a potent immune response.  While there are many components to the 
immune system there are a few key players: dendritic cells and lymphocytes (CD4+ and 
CD8+).  Dendritic cells (antigen presenting cells) are thought to be the sentinels of the 
immune system because they are able to engulf, process and present antigens to T-
lymphocytes and trigger an immune response (320).  There are two different classes of 
antigens found on cell surfaces which T cells react to, major histocompatibility complex I 
(MHCI) and major histocompatibility complex II (MHCII).  MHCI are present on all 
cells and alert cytotoxic T cells (CD8+ or killer T cells) to directly attack and eliminate 
the foreign invader (321).  Whereas, MHCII are only found on certain cells, such as B 
cells and macrophages, and recruit helper T cells which are responsible for orchestrating 
the immune response (322).  Moreover over the interaction between dendritic cells and T 
lymphocytes can elicit different cytokine secretions called Th1 or Th2 responses(323) .  
Th1 is pro-inflammatory response and is linked with activation of cytotoxic T cells and a 
predominant cytokine which is released is IFN-γ.  Th2 responses are anti-inflammatory 
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and involve the secretion of interleukin-10 (IL10).  The regulation of the immune system 
is an intricate balance which includes many players in order to rid our body of any 
harmful invaders.   
 While classic invaders are viruses, bacteria and parasites, cancer cells are also 
foreign to our body.  When normal cells transform into cancer cells some of their cell 
surface antigens change and these new or altered antigens potentially can induce an 
immune response.  While our body does mount a response to the growth of cancer cells, 
most of the time the immune system ultimately fails for many reasons.  One reason is that 
the body is constantly undergoing immunosurvelliance however this process either 
breakdowns or it becomes overwhelmed by the rapid proliferation of cancer cells.  
Secondly, while cancer does have a percentage of non-self antigens it also displays self 
antigens allowing it to circulate under the radar of the immune system.  Thirdly, cancer 
cells might be able to hide or disguise their non-self antigens to evade an immune 
response.  Lastly, cancer cells might upregulated proteins that suppress an immune 
response.   
 Melanoma has long been recognized as an immunogenic tumor that elicits an 
immune response however has developed mechanisms to suppress an anti-cancer immune 
response.  The interplay between melanoma and the immune system has been known for 
many years with melanoma being one of the only tumors that has been shown to 
spontaneously regress which is thought to involve the immune system.  Secondly, 
analysis of melanoma patients have indentified that circulating T cells have responded to 
melanoma because they carry different melanoma antigens such as tyrosinase, MART-
1/Melan-A, gp100, TRP1 and TRP2 (324-329).  Moreover, the microenvironment in 
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melanoma has been shown to be highly immunosuppressive with evidence of tolerogenic 
dendritic cells and suppressor T lymphocytes present in melanoma at all stages of disease 
progression (330).  Furthermore, the presence of the immune cells in the 
microenvironment and the tumor itself correlates with a better prognosis.   
The use of immunotherapies has focused on the treatment of melanoma because 
of its interaction with the immune system.  IL2 and IFNα  have been shown to have 10% 
to 20% response rate in melanoma and these chemokines play pivotal roles in regulating 
the immune system  (20-23).  Recently, dendritic cell-based vaccines, either pulsed with 
melanoma cells, lysates, peptide or antigens,  have been used to treat melanoma patients, 
however with little success (26, 27).  The failure of these DC based vaccines has evoked 
interest into how dendritic cells interact with melanoma cells and T cells.  Surprisingly, 
research has demonstrated that melanoma cells inhibit the interaction between dendritic 
cells and T cells or Natural killer cells suppressing the immune response (331).  Gene 
expression analysis of melanoma cell lines identified CD200, a protein which negatively 
regulates the immune system, as a novel target of p-ERK signaling in melanoma, 
suggesting that expression of CD200 is another way melanoma possibly evades an 
immune response (264). 
A.  CD200: an immunosuppressive molecule 
 The immune system has evolved to orchestrate two opposing tasks; to protect the 
body against potentially harmful pathogens while preventing excessive immune reaction 
leading to tissue destruction.  One way the immune system is able to do this is through 
the interaction between CD200 and its structurally related receptor (CD200R).  CD200 is 
member of the immunoglobulin super family domain (IgSF)-bearing molecules which is 
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the most abundant molecules found on the cell surface, constituting about one third of the 
proteins found on the surfaces of leukocytes (332).  CD200 has two Ig-like extracellular 
domains, one transmembrane domain, and a cytoplasmic domain which has no known 
signaling function.  It is expressed on a variety cell types and tissues including: 
thymocytes, T cells, B cells, kidney glomeruli, tonsil follicles, the placenta, ovary, 
vascular endothelium and neurons (333-336).  CD200 induces an immunosuppressive 
signal through its structurally related receptor CD200R (337).  CD200’s role in 
negatively regulating the immune system has been shown in spontaneous abortions, 
prolonging graft survival and tumor rejection (333-336, 338-340).  Moreover, CD200 is 
expressed on many human viruses, such as herpes virus 8 and has been implicated in 
down regulating T cell and dendritic cell activation as well as modulation of the host-
pathogen immune reaction (341, 342).  To elucidate the role of CD200 in the immune 
system, CD200 knockout mice were generated (343).  These mice developed normally, 
but had an increase of macrophages in the spleen and liver and an increase  of microglia 
in the brain.  However, these mice were highly susceptible to experimentally-induced 
autoimmune diseases.  In response to nerve damage, induced through facial nerve 
transaction, CD200 knockout mice had a dramatic increase in microglia activation when 
compare to wild type mice. To test CD200 function in myeloid linage compartments, 
CD200 knockout mice were treated to develop both experimental autoimmune 
encephalomyelitis (EAE) and collage-induced arthritis.  CD200 deficient mice were 
highly susceptible to both conditions when compared to wild type and showed a 
significant increase of macrophages and self-reactive T cells.  These findings suggest that 
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CD200 controls the induction of an immune response, and lack of CD200 causes an 
exaggerate immune response leading to autoimmunity (343). 
 The N-terminal domains of both CD200 and CD200R are critical for their 
interaction and for the negative immune signal to occur (344).  The N-terminal surface of 
CD200 is highly glycosylated to prevent any cis interactions; however it still displays the 
binding face which interacts with the CD200R.  While the CD200-CD200R interaction is 
similar to CD80 and CD86 and its interaction with either CD28 (positive) or CTLA4 
(negative) the CD200R transmits its single in different ways (345, 346).  The CD200R 
has two Ig like domains, and one cytoplasmic tail which contains a NPXY signaling 
motif.  The CD200R is mainly expressed on myeloid cells such as macrophages, 
dendritic cells and neutrophils, but it can also be found on T cells.  There is little known 
about how CD200R elicits its downstream signaling; however some research has 
demonstrated that its NPXY motif binds to a phosphotyrosine domain present in 
signaling adaptor molecules.  It has been demonstrated in mast cells that both Dok1 and 
Dok2 phosphorylate CD200R and this inhibits downstream activation of the RAS-RAF 
signaling pathway (347).  Moreover, Src family inhibitors such as PP2, repressed the 
phosphorytalion of CD200R through Dok1, which suggests that the interaction between 
Dok1 and CD200R is mediated by the Src family of kinases (348).   
 The skin is highly immunogenic and is one of the first barriers against pathogens; 
therefore it is not surprising that both CD200 and CD200R are expressed on certain cell 
types in the skin.  Extensive analysis of murine hair follicles, identified CD200 as major 
contributor it the stem cell behavior of hair follicles and demonstrated that CD200 
allowed for the immune-privileged state by attenuating inflammatory immune  
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reactions (349, 350).  CD200R expression was also identified in the skin with rare 
expression on Langerhans cells, a type of macrophage found in the skin.   
CD200-CD200R role in suppressing the immune response has implicated it’s role 
in cancer, and the ability of cancer to elude the immune reaction.  Recently, several  
Studies have shown an over expression of CD200 in certain cancers, as well as 
demonstrated a function role of CD200 in the pathogenesis of a variety of cancers.  
Analysis of cell surface proteins on chronic lymphocytic leukemia identified CD200 as a 
potential molecule involved CLL (351).  Using mixed lymphocytic reactions (MLRs) of 
dendritic cells, T cells and primary CLL cells, researchers demonstrated that antibodies 
against CD200 restored Th1 cytokine production (IL2 and IFNγ) from a Th2 response.  A 
switch from a Th1 response to a Th2 response has been seen in cancer progression, which 
suggests that inhibition of CD200 could restore a Th1 response and help treat certain 
types of cancers.  Using Affymetrix microarrays, CD200 was determined to be 
upregulated in both multiple myeloma (MM) (352) and acute myeloid leukemia (AML) 
(353).  Furthermore CD200 expression correlated with poor prognosis in both MM and 
AML, suggesting CD200 could be a potential therapeutic target in MM and AML.  In 
addition to CLL, AML, and MM a gene expression profile array of melanoma cells with 
different status of ERK activation identified many novel targets of ERK activation in 
melanoma, including CD200 (264).  Moreover, two additional studies  of melanoma cell 
lines demonstrated that CD200 was overexpressed and abrogating CD200 function 
through monoclonal antibodies or knockdown showed an induction of Th1 cytokine 
expression (354, 355).  Moreover, CD200 expression seemed to correlated with the 
progression of melanoma.  CD200 potent suppression of the immune system not only 
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Figure 9 
 
 
 
 
 
 
 
 
The role of CD200 in melanoma.  A) The RAS-RAF-MEK-ERK pathway is commonly 
upregulated in melanoma; novel ERK targets in melanoma include CD200.  B) CD200 
interacts with its structurally related receptor which elicits an immune-suppressive signal and 
potentially allows melanoma to evade an immune response. 
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prevents autoimmunity but can contribute to the pathogenesis of many different cancers, 
including melanoma. 
B. Summary: Potential Therapeutic Target 
 The immune system is a potent anti-tumor mechanism; however a variety of 
cancers are able to continuously evade the immune response.  Targeting molecules 
involved in cancers ability to escape the attack is a potential area to develop therapeutic 
agents for cancers.  Melanoma is a highly rational target for immunotherapies because of 
its relationship with the immune system. Not only does melanoma elicit an immune 
response with melanoma patients harboring circulating T-cells targeted with melanoma 
antigens, melanoma has been shown to express CD200, an immunosuppressive molecule, 
to down-regulated any immune response.  While melanoma is a complex disease with 
many genetic and environmental factors, it also has a variety of mechanisms to 
breakdown our highly efficient immune system. 
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Chapter 
 IV. Somatic loss of p16Ink4a and activation of Ras induces melanoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.  Abstract 
The incidence of melanoma has doubled over the last 3 decades due to increased 
recreational exposure to UV light.  Melanoma is recognized for its proclivity to early 
metastasis and resistance to therapy.  An improved understanding of the disease 
pathogenesis coupled with enhanced murine models will be vital to the development of 
improved therapies. The p16INK4a-RB and ARF-p53 tumor suppressor pathways are 
compromised in nearly all human melanomas.  Previous models of murine melanoma 
have relied on germline deletions of these tumor suppressor genes. While heterozygous 
germline mutations of p16INK4a are associated with familial melanoma, most melanomas 
harbor somatic p16INK4a loss, with a significant minority also harboring somatic p53 
inactivation.  Here, we employ a novel p16Ink4a conditional allele along with conditional 
p53 and K-Ras alleles to better model human melanoma.  We found that there is potent 
synergy between melanocyte-specific loss of p16Ink4a and/or p53 with activation of K-Ras 
in melanomagenesis.  Additionally, somatic inactivation of p16Ink4a and p53 with 
concomitant K-Ras activation rapidly induces melanoma even in adult mice, suggesting 
there is no ‘developmental window’ for melanocyte transformability.  This work provides 
an improved experimental platform for the study of human melanoma, and suggests that, 
from the point of view of melanomagenesis, even adults are not safe from the oncogenic 
effects of mutagenic sun exposure. 
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B.  Introduction  
Melanoma, the most lethal form of skin cancer, is increasing incidence and 
mortality in the US (reviewed in (1)).  There are three common genetics events that 
characterize the majority of melanoma:  activation of the RAS-RAF-ERK pathway, 
inactivation of the p16INK4a-CDK4-RB pathway and inactivation of the ARF-p53 
pathway.  The RAS-RAF-ERK pathway is a mitogen activated kinase cascade, which has 
induces a transcriptional signature associated with increased proliferation, survival, 
motility and immune surveillance resistance (264, 354, 356).  In human melanoma, 
activating mutations of N-RAS occur in 21% of tumors, of K-RAS in 3% of tumors and 
of B-RAF in 44% of tumors (Catalogue of Somatic Mutations in Cancer (COSMIC)).   
The INK4a/ARF (aka CDKN2a) locus at 9p21 encodes two different tumor 
suppressor proteins, p16 INK4a and ARF, both of which appear to play an important role in 
melanoma suppression (reviewed in (reviewed in (95, 357)). Deletion of the INK4a/ARF 
locus occurs in 50% of human melanomas, making it the most common site of genomic 
loss in this disease (47), with homozygous deletion being relatively common (358).  Such 
deletions generally inactivate p16INK4a, ARF and p15INK4b, a close homologue of p16INK4a 
encoded by the linked CDKN2b locus.  Expression of ARF stabilizes p53, whereas 
p16INK4a and p15INK4b expression lead to RB-hypophosphorylation and cell cycle arrest.  
Of these tumor suppressor proteins, particularly strong evidence indicates that p16INK4a is 
a potent melanoma tumor suppressor:  germline mutations affecting only p16INK4a are 
associated with familial melanoma (119) and somatic missense mutations of p16INK4a that 
do not affect ARF or p15INK4b are common in sporadic tumors.  Likewise, although p53 
loss is seen in 10-30% of melanoma (189, 190), inactivation of ARF appears to be the 
more common lesion of the ARF-p53 tumor suppressor pathway in this tumor type.    
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The presence of activating B-RAF mutations in a high proportion of dysplastic 
nevi indicates aberrant activation of RAS-RAF pathway is not sufficient for 
tumorigenesis and additional genetic lesions must occur (15).  Strong RAS-RAF 
activation has been shown to induce p16INK4a expression and ‘oncogene-induced 
senescence’ in several human in vitro systems, suggesting a mechanistic basis for 
cooperation between p16INK4a loss and RAS-RAF activation (359).   
Against this backdrop, however, the murine modeling data have been somewhat 
difficult to reconcile.  Several genetically engineered mouse models of melanoma have 
been developed by employing constitutively active transgenes and germline knockout 
alleles.  One current melanoma model uses a melanocyte specific activated H-RasV12G 
allele on an Ink4a/Arf deficient background (312).   The dermal melanomas that 
developed are amelanotic, locally invasive, and lacked evidence of metastasis.  Further 
analysis, using a doxycycline inducible H-Ras allele on an Ink4a/Arf deficient 
background, determined that activation of H-RasV12G is essential for both the initiation 
and maintenance of melanomas (249).  In order to determine the role of p53 in 
melanoma, the H-RasV12G allele was crossed on to a p53 deficient background (316).  
Dermal melanomas that developed were histologically similar to melanomas from 
TyrRasInk4a/Arf-/- mice.  In contrast to these models driven by transgenic H-Ras 
expression, mice expressing a constitutive, melanocyte -specific mutant allele of N-Ras 
in an Ink4a/Arf deficient background develop melanotic, multifocal tumors that 
metastasize to lymph node, the lung and liver (311).  Whether these differences in 
pigmentation and metastasis reflect differences in RAS biology or technical features of 
the differing transgenic models is unknown.   
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  While these mouse models of melanoma have been used to filter out the 
complexity of genetic pathways involved in the pathogenesis of melanoma, their use of 
knockout alleles and constitutively active transgenes questions their efficacy in modeling 
human melanoma.  Germline knockout alleles of both the Rb and p53 pathways have 
brought to the forefront that tumor suppressors may play different roles in mice and 
humans. Familial cancer syndromes such as familial atypical multiple mole melanoma 
(FAMMM) have been show to disrupt p16INK4a function through mutations or deletion, 
while keeping ARF functionally intact, suggesting that p16INK4a is the bona fide tumor 
suppressor of the INK4a/ARF locus in certain human cancers. However, germline 
knockout models of the Arf-p53 pathway have shown striking tumor prone phenotypes 
with a wide spectrum of tumor types and short latencies (170, 182, 360, 361).  While, 
p16Ink4a germline knockout models have produced a weak tumor prone phenotype when 
compared to germline knockout models of p53, Arf and Ink4a/Arf, suggesting that the 
loss of Arf is more important in mice (135, 136).  It is not clear if these discrepancies 
reflect mouse versus human differences or reflect deficiencies in the models.  Therefore, 
the use of germline knockout alleles in mice raises questions about how closely they 
mimic mutations of both tumor suppressor genes and oncogenes found in human sporadic 
cancers. For this reason we have employed the use of conditional alleles to generate a 
better mouse model of melanoma.   
Epidemiological studies have suggested that childhood sun exposure rather than 
sun exposure later in life poses a higher risk of developing melanoma (reviewed in 
(362)).  Children who live in ambient sun exposure areas have been shown to have an 
increase in nevi formation and a higher risk for developing melanoma (3-5, 363) This has 
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suggested that melanocytes during early development have a higher potential to acquire 
initiating mutations; therefore increasing their potential to develop into melanomas.   In 
order to understand this relationship in GEMMs, HGF/SF transgenic mice were treated 
with ultraviolet B (UVB) at 3.5 days or at 6 weeks (317).  HGF/SF transgenic mice 
treated with UVB as neonates developed melanomas at a short latency and with high 
penetrance, while HGF/SF transgenic mice treated with UVB as adults were resistant to 
tumor formation.  This suggests that a ‘developmental window’ exists for melanocytic 
mutations.  To evaluate the ‘developmental window’ in mice, we manipulate conditional 
alleles of potential UVB targeted pathways to determine if recombination of these alleles 
in adults is as tumorigenic as recombination of these alleles in neonates.     
In this work, we show that somatic loss of p16Ink4a and p53 combined with 
somatic activation of K-Ras is highly oncogenic.  Loss of either single is also oncogenic, 
and in p53 deficient tumors, we saw evidence for progression through somatic p16Ink4a 
inactivation.  This is in contrast to the results obtained using germline alleles, suggesting 
developmental compensation in p16Ink4a -Cdk4-Rb and Arf-p53 pathways explains the 
mouse-human discrepancies rather than differences in species’ biology.  Moreover, this 
trio of genetic events efficiently induced melanoma in adult mice, suggesting there is no 
‘developmental window.’    
C.  Results  
To investigate the role of conditional and somatic loss of p16Ink4a and/or p53 in 
the setting of somatic K-Ras activation, a melanocyte-specific inducible CRE allele (Tyr-
CRE-ERT2) was crossed with three conditional alleles: Lox-Stop-Lox KrasG12D (364), 
p53L/L (365), and a newly generated floxed p16Ink4a allele (termed p16L/L) (Figure 11). 
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The floxed p16Ink4a allele was generated by inserting a loxP site ~3.5 kb 5’ to exon 1α and 
another in the first intron of p16Ink4a 3’ to exon 1α (Figure 12).  We chose to place the 5’ 
LoxP site at this distance from the start codon by replacing a polymorphic repetitive 
element that is not conserved between 129SvJ and C57Bl/6, and therefore likely not a 
critical Ink4a/Arf regulator.  Further description of the allele production is available in the 
methods.   CRE expression in cells homozygous for this allele demonstrated selective 
p16Ink4a excision and rapid loss of p16Ink4a protein expression (Figure 12).  As opposed to 
other germline p16Ink4a and Arf KO alleles, no alteration was seen in the expression of the 
remaining Ink4/Arf locus proteins (e.g. p15Ink4b and Arf) in CRE-treated MEFs (data not 
shown) 
The four alleles were intercrossed to produce Tyr-CRE-ERT2 
KRASLSL/+p16L/Lp53L/L animals (abbreviated TKp16L/Lp53L/L). In a subset of mice, CRE 
recombination was confirmed by also crossing in a reporter allele (Rosa26-LSL-β-
galactosidase, (313)) and recombination confirmed by β-gal staining (Figure 10).   
Littermate cohorts of TKp16L/Lp53L/L mice with indicated control animals were topically 
treated as neonates with 4-hydroxytamoxifen (4-OHT) to induce CRE recombination in a 
small percentage of melanocytes as previously described  (Figure 13) (313).  After 8 to 
14 weeks, all 4-OHT-treated TKp16L/Lp53L/L mice developed aggressive tumors requiring 
euthanasia.  In contrast, TKp16+/+p53+/+ mice were only weakly prone to melanoma, with 
only 1 of 14 treated mice developing a melanoma at 60 weeks post-treatment (Figure 14, 
Table 7).  TKp16L/Lp53L/L mice did not develop melanoma in the absence of 4-OHT 
treatment, and non-melanoma tumors were not observed in 4-OHT- treated 
TKp16L/Lp53L/L mice.  These data demonstrate potent cooperation in melanomagenesis  
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 Figure 10 
 
 
 
CRE recombination in melanocytes.  CRE recombination in melanocytes 
located in the hair follicle (A, C, D) and in the epidermal-dermal junction (B) and 
in tumors (E, F) confirmed by β-gal staining. 
 
 
75 
 
  
 
 
 
 
Conditional Alleles A) The tyrosinase CREERT2 allele to generate melanocyte specific 
expression of target alleles.  B) The LSL-KRasG12D allele which contains a stop codon 
after the exogenous promoter and upon CRE recombination the stop codon is removed 
and a constitutively active KRasG12D is expressed.  C) The p53flox allele contains loxP 
sites that encompass exons 2 through 10, and generates a null allele after CRE activation.  
D) The p16Ink4aL/L allele contains loxP sites that surround only exon 1α; therefore only 
abrogating p16Ink4a function. 
Figure 11 
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 Generation of the p16Ink4aL/L allele.  A) The endogenous p16Ink4a locus with exons (red 
boxes), restriction sites, southern probes (red lines), and p19Arf exon 1B (blue box).  The 
targeting construct for homologous recombination with loxP site (blue triangle).  Frt sites 
(purple box), neo allele (blue arrow) and restriction sites.  B) Right Arm southern blot of 
genomic tail DNA probed with Not1 digest.  Un-recombined littermates, lanes 1,3.  
Successful recombination, lane 2. Untargeted C57Bl/6 control DNA, lane 4. C) Left Arm 
southern blot of genomic tail DNA probed with NheI digest.  Un-recombined littermates, 
lanes 6, 8.  Successful recombination, lane 7. Untargeted C57Bl/6 control DNA, lane 5. 
D) Western blot of murine embryonic fibroblasts (MEF) lysates with and without adeno-
cre. L=p16 conditional (floxed) allele. 
 
Figure 12 
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 Figure 13  
Schematic of conditional allele activation.  For neonate treatment, pups are 
treated with 4-OHT for 3 consecutive days.  CRE activation induces somatic 
deletion of both p16IInk4a and p53 while activating a mutated KRasG12D.  For 
adults, fur is removed through a depilatory agent and then the area is treated with 
4-OHT.  Tumors developed at the location of fur removal. 
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between homozygous inactivation of p16Ink4a and p53 with single copy, endogenous K-
Ras activation.  
 Mice from all cohorts, (TKp16+/+p53+/+, TKp16L/L, TKp53L/L, and TKp16L/Lp53L/L) 
developed melanocytic proliferation in the skin prior and during tumor formation.  Paws 
of treated mice from all cohorts developed pigmented macuoles, which is also seen in the 
tail (Figure 18a, b).   Untreated wildtype animals had little melanin production in sections 
of the ear when compared to all treated mice from each cohort.  Skin from 
TKp16L/Lp53L/L treated mice had an increase of melanin production when compared to 
either TKp16+/+p53+/+, TKp16L/L or TKp53L/L (Figure 18c).  Furthermore, a potential 
nevus with melanocytic proliferation and melanin production was identified in a section 
of ear from TKp16L/L treated mouse (Figure 19).  This suggests that transformation is 
occurring in melanocytic compartments post 4-OHT treatment and proliferation rates or 
additional genetic aberrations affect the potential for tumor development. 
To elucidate the roles of each tumor suppressor mechanism in the development of 
melanoma, Tyr-CRE-ERT2 KRasLSL/+ expressing mice were crossed to either p16L/L or 
p53L/L mice to yield TKp16L/L and TKp53L/L animals.  Cohorts of these animals were 
treated neonatally by topical 4-OHT and followed for tumor development as in (Figure 4-
5, Table 4-1).  In contrast to results obtained using germline deficient alleles (135, 136, 
170, 182, 316), somatic, melanocyte-specific loss of p16INK4a was as tumorigenic in this 
system as somatic loss of p53 (Figure 4-5).  Both combinations had significantly shorter 
tumor latencies than seen in the TKp16+/+p53+/+ mice, and significantly longer latencies  
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The loss of p16Ink4a and p53 with Ras activation induces melanoma.  A)  Melanoma 
Kaplan-Meier survival analysis of TK only, TKp16L/Lp53L/L, TKp1 L/L, TKp53L/L. 
Differences between TK vs. TKp16L/L, TK vs. TKp53L/L are statistically significantly (p 
< 0.0001), differences between TKp16L/Lp53L/L vs. TKp16L/L and TKp16L/Lp53L/L vs. 
TKp53L/L are statistically significantly (p < 0.0001), and differences between TKp16L/L 
vs. TKp53L/L are not statistically significantly.   
Figure 14 
6
Figure 15 
Analysis of TKp16L/Lp53L/L tumors.  A) Analy Insis of p15 k4b and ARF in TKp16L/L
tumors showed no expression of p15INK4b and increased expression of ARF. B)  Anal
p15Ink4b and ARF in TKp16L/Lp53L/L tumors showed no expression of phosphorylate
p16Ink4a or p21Cip1 (p53 target). 
p53L/L 
ysis of 
d p53, 
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Immunohistochemical analysis of melanomas 10X. Tumors from each cohort (A-D), 
ogy through H&E staining (E-H)  and stained positive 
r tyrosinase related protein 1 (TRP1) (I-L) and Ki67, a marker of proliferation (M-P).  
Original magnifications 100X. 
 Figure 16 
exhibited a spindle-like morphol
fo
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Immunohistochemical analysis of melanomas 20X. Tumors from each 
cohort stained positive for tyrosinase related protein 1 (TRP1), tyrosinase 
related protein 2 (TRP2) and Ki67, a marker of proliferation.  Original 
magnifications 200X. 
 
 Figure 17 
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Melanocytic proliferation in the skin.  Pigmented macuoles located on the paws (A) 
and tail (B) were found on all 4-OHT treated animals when compared to untreated 
wildtype controls.  Melanocytic proliferation and melanoma production was observed in 
skin sections found in all treated mice from each cohort (C).   
 Figure 18 
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Melanocytic precursor.  A potential nevus found in a section of 4-OHT treated ear 
from a TKp16L/L mouse. Identified through proliferation of the skin and melanin 
granules located in the area of skin.  Original magnification 100X, 200X and 400X.  
Figure 19 
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Figure 20 
Genetic analysis of TKp16L/Lp53L/L tumors. A) 100% recombination efficiency 
for conditional alleles in tumors.  B) Multiplicity of tumors found in 
TKp16L/Lp53L/L when compared TKp16+/+p53+/+, TKp16L/L, TKp53L/L tumors. 
 Figure 21 
p53 path
either int
response
intact p53 and was absent in p53 null cell lines.  ARF function was still intact in 
KRASp16p53 cell lines. 
way in murine melanoma cell lines.  Mouse melanoma cell lines with 
act p53 function or null for p53 function were treated with doxorubicin.  p53 
, measured by levels of p-p53. p21Cip1 and BAX, occurred in cell lines with 
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than seen in the TKp16L/Lp53L/L cohort.  There was no significant difference in the 
latencies between 4-OHT treated TKp16L/L (24 weeks) and TKp53L/L (31 weeks) animals.   
All tumors from the 4 cohorts (TKp16+/+p53+/+, TKp16L/L, TKp53L/L, and TKp16L/Lp53L/L) 
exhibited a spindle-like morphology with little or no pigmentation and positive staining 
for TRP1 and TRP2 (Figure16, 17).  All tested tumors demonstrated recombination of the 
K-Ras, p16Ink4a and p53 alleles by PCR (Figure 20a).  These “amelanotic” melanomas are 
similar to those reported by Chin in colleagues using H-Ras in Ink4a/Arf-deficient mice 
(TyrRasInk4a/Arf-/-respectively), but different than the melanomas described in the N-
Ras Ink4a/Arf-deficient mice, which were pigmented and metastasized.  In contrast to the 
TyrRasInk4a/Arf-/- model where tumors are limited to ears, trunk, tail and uvea, tumors 
occurred on the flank, ear and tail, and no uveal tumors were seen.  Multiple tumors were 
seen on treated TKp16L/Lp53L/L mice when compared to treated mice from 
TKp16+/+p53+/+, TKp16L/L, TKp53L/L, which on average only developed one tumor per 
mouse (Figure 20b).  Western blot analysis of p16Ink4a and p53 expression of 
TKp16L/Lp53L/L tumors demonstrated that neither p16Ink4a nor p53 were expressed in these 
tumors; furthermore p21Cip1 expression was undetectable in these tumors as well, 
confirming that p53 signaling was abrogated in these tumors (Figure 15b). 
To further characterize melanomas from TKp16L/Lp53L/L mice, cell lines were 
generated as previously described (366). To ascertain Arf-p53 pathway function, cell 
lines were treated with doxorubicin, a DNA-damaging agent.  While phospho-p53 and 
expression of p53 targets (p21Cip1 and Bax) were sharply induced by doxorubicin 
treatment in cell lines from p53+/+ and p53L/+ tumors (all intact p53 cell lines were 
generated from TyrRasInk4a/Arf-/- tumors), no p53 response was noted in tumor cell 
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lines generated from 4-OHT-treated TKp16L/Lp53L/L mice (Figure 21).  Moreover, Arf 
protein expression was markedly increased in cell lines from TKp16L/Lp53L/L mice (Figure 
15a, 21), in accord with prior results showing Arf over-expression in cancers lacking 
functional p53 (182).  These data indicate p53 inactivation in tumors of TKp16L/Lp53L/L 
mice.  
To determine the effects of both the p16Ink4a-Cdk4-Rb and Arf-p53 pathways in 
melanocyte transformation, tumor lysates from both TKp16L/L and TKp53L/L mice were 
analyzed.  Analysis of p53 activation in TKp16L/L tumors showed that a majority of 
tumors retained p53 function (Figure 22).  However, most TKp16L/L tumors demonstrated 
a decrease in Arf expression.  Of note, one TKp16L/L tumor lost p53 expression and 
subsequently had an increase in ARF expression levels when compared to p53 intact 
TKp16L/L tumors (Figure 24a).  Analysis of the p16Ink4a-Cdk4-Rb pathway in TKp53L/L 
tumor lysates demonstrated that 50% of tumors downregulated p16Ink4a expression 
(Figure 23a).  This result was unexpected based on a previous report using Tyr:H-
Rasp53-/- mice which developed melanomas with intact p16Ink4a expression, suggesting 
other components of the p16Ink4a-Cdk4-Rb pathway were altered in the tumors (316).  
Therefore, in contrast to prior murine results using germline alleles but in accord with the 
genetics of human melanoma, we observe that somatic p16INK4a inactivation is as 
oncogenic, if not more so, than somatic p53 loss with regard to melanomagenesis. 
Interestingly, p15Ink4b has been shown to play a ‘back-up’ tumor suppressor role 
in p16Ink4a germline deficient animals (96, 367).  A majority of tumor lysates from 
TKp16L/Lp53L/L tumors did not demonstrate detectable p15Ink4b expression (Figure 15a).  
This result suggests that either the compensatory increase of p15Ink4b expression does not  
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Figure 22  
The p53 pathway in TKp16L/L tumors. Analysis of p53 expression in tumors 
demonstrated that half of the TKp16L/L tumors retain p53 expression.    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 
 
Analysis of TKp16L/L, TKp53L/L, and TKp16L/Lp53L/L tumors.  A)  TKp53L/L 
tumor lysates had 50% p16INK4a expression while TKp16L/L lost ARF expression. 
B) Tumor lysates from all the cohorts (TKp16L/L, TKp53L/L, and TKp16L/Lp53L/L) 
expressed varying degrees of p15Ink4b. 
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Figure 24 
 
 
 
Molecular Analysis of Tumors.  A)  Analysis of p53 and Arf expression in TKp16L/L 
tumors.  p-p53 expression remains intact for most of TKp16L/L tumors; however the one 
tumor which loses p53 expression has increased Arf expression.  B)  Analysis of different 
heterozygous tumors demonstrated a selective pressure against p16Ink4a expression and not 
Arf expression. 
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Figure 25 
Melanoma Kaplan-Meier survival analysis of heterozygous tumors.   
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occur in the setting of somatic, as opposed to germline deletion, of p16Ink4a; or that 
p15Ink4b is not expressed in melanocytic lineage cells. Futher analysis of p15Ink4b 
expression in tumor lystates from TKp16L/L and TKp53L/L demonstrated that p15Ink4b is 
expressed is some percentage of each tumor type.  Strinkingly, TKp16L/L tumors 
expressed lower levels p15Ink4b when compared to TKp53L/L tumors, suggesting that 
somatic loss of p16Ink4a induces a negative down regulation of the Ink4a/Arf/Ink4b locus 
(Figure 23b).    
To explore what happens to the intact alleles, tumors lysates were analyzed from 
TKp16L/+p53L/+, TKp16L/+p53L/L and TKp16 L/Lp53 L/+ treated mice.  Surprisingly, p16Ink4a 
expression was lost in the majority of tumors from all cohorts, with only 1 tumor from 
TKp16L/+p53L/+ retaining p16Ink4a expression indicating that p16Ink4a expression is 
selected against in melanocytes. Moreover, Arf expression was absent in this tumor, 
suggesting the Ink4a/Arf locus was targetd for deletion (Figure 24b).  Arf expression was 
not consistent in all tumor cohorts.  TKp16L/Lp53L/L tumor lysates all expressed Arf, while 
tumors from TKp16L/+p53L/+, TKp16L/+p53L/L and TKp16 L/Lp53 L/+ had varying levels of 
Arf expression, suggesting the need to delete Arf is not as necessary as deletion of 
p16Ink4a in melanomas (Figure 24b).  Furthermore, the tumor latencies of TKp16L/+p53L/L 
and TKp16 L/Lp53 L/+ were significantly different suggesting that single copy loss of either 
p16Ink4a or p53 has different effects on tumor development.  The TKp16L/+p53L/L tumor 
latency was was similar to the TKp16L/Lp53L/L tumor latency, suggesting that the effect of 
single copy loss of p16Ink4a along with p53 homozygous deletion is as tumorigenic as the 
effect of losing both p16Ink4a and p53 in melanocytes, indicating that p16Ink4a is an 
important inhibitor of tumor development.  However, the latency of TKp16L/Lp53L/+ was 
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slower than TKp16L/Lp53L/L tumor latency suggesting that deactivating only one allele of 
p53 potentially activates the wildtype allele to repress aberrant proliferation (Figure 25). 
In order to define this new mouse model of melanoma, we compared the tumors 
of TKp16L/Lp53L/L to an already established mouse model of melanoma reported by Chin 
in colleagues using H-Ras in Ink4a/Arf-deficient mice (Figure 26b) (312).  The growth 
rates of these two tumor types were strikingly different both in vivo and in vitro.  At day 
6, the TKp16L/Lp53L/L tumors began to proliferate rapidly and were approximately twice 
the size of TyrRasInk4a/Arf-/- tumors by day 8.  Futhermore, in vitro analysis of tumor 
derived cell lines, demonstrated an increase in S phase and aneuploidy of the 
TKp16L/Lp53L/L derived cell lines when compared to TyrRasInk4a/Arf-/-, most likely due 
to the loss of p53 function in TKp16L/Lp53L/L tumor cell lines (Figure26a, 27c). While 
TKp16L/Lp53L/L and TyrRasInk4a/Arf-/- tumors grow at different rates, the tumor latencies 
of both models are similar (Figure 26b), suggesting that either different isoforms of Ras, 
somatic loss of tumors suppressors or the loss of p53 could play a role in their drastic 
growth rates.   To determine any compensatory effects other tumor suppressors might 
have due to the loss of both p16Ink4a and p53: Arf, p15Ink4b, p21Cip1 and p27Kip1 expression 
levels were all analyzed (Figure 26d). Due to the loss of p53, Arf levels were elevated; 
however, the striking decrease in p21Cip1 in the TKp16L/Lp53L/L tumors suggests that loss 
of p53 in this melanoma model is important for tumorigenesis (Figure 26d).  In addition, 
targets of Ras were analyzed in order to determine if different Ras isoforms contribute to 
the aggressive behavior of the tumor types; however no difference was observed (Figure 
27a).   
Furthermore, the TKp16L/Lp53L/L tumors were highly angiogenic and necrotic 
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Figure 26 
 
 
 
 
The aggressive behavior of TKp16L/Lp53L/L tumors. A) In vivo analysis of tumor size of 
TKp16L/Lp53L/L and TyrRasInk4a/Arf-/-tumors. B) A gross picture of both TyrRasInk4a/Arf-
/- and TKp16L/Lp53L/L tumors. The TKp16L/Lp53L/L tumors are  darker in color due to necrosis 
and increased vasculature.  C)  Western blot analysis of Hif1α, shows an increase in 
expression of Hif1α in TKp16L/Lp53L/L tumors.  D) Western blot analysis of Arf, p21Cip1, 
p27Kip1.  Increased levels of p21Cip1 in TyrRasInk4a/Arf-/-tumors suggest loss of p53 
contributes to TKp16L/Lp53L/L aggressive behavior.  E) Immunohistochemsitry for CD34 
shows a slight increase in blood vessel formation in TKp16L/Lp53L/L when compare to 
TyrRasInk4a/Arf-/-. 
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Figure 27 
Molecular analysis of K-Ras and H-Ras tumors.  A) Analysis of different Ras 
targets shows no significant difference between KRas activation versus HRAS 
activation.  B) Melanoma Kaplan-Meier survival analysis of tumors shows no 
significant difference between the two tumor types.  C) In vitro analysis of the cell 
cycle in tumor cell lines generated from TKp16L/Lp53L/L and TyrRasInk4a/Arf-/-shows 
a decrease in G1 phase.  
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suggesting that hypoxia inducible factors could contribute to the aggressive phenotype of 
TKp16L/Lp53L/L tumors.  Analysis of Hif1α expression, demonstrated a slight increase in  
TKp16L/Lp53L/L when compared to the TyrRasInk4a/Arf-/- tumors, suggesting the Hif 
pathway is upregulated in TKp16L/Lp53L/L tumors (Figure 26c).  To support the role of 
Hif1α in TKp16L/Lp53L/L, CD34 staining was performed to confirm an increase in blood 
vessel formation in the TKp16L/Lp53L/L tumors; however only a slight increase of staining 
was observed suggsesting the role of p53 may be the main contributor to the observed 
aggressive phenoytpe (Figure 26e)   
The risk of developing melanoma has been strongly associated with periods of 
intense intermittent sun exposure and sunburn during childhood rather than adulthood 
(reviewed in (363)).  Mouse models using ultraviolet radiation (UVR) have shown that 
UVR induces melanoma in neonates and adult mammals are resistant to melanoma 
formation (317, 318).  In order to investigate the tumorigenic potential of somatic loss of 
p16Ink4a, p53 and activation of KRas in adult mice, we treated TKp16L/Lp53L/L mice with 
4-OHT as neonates or at 8 weeks of age.  Neonates were treated as previously discussed.  
For adult mice, a selected area of hair was removed with a depilatory agent and then 
treated with 4-OHT for three consecutive days (Figure 13).  Both cohorts of mice were 
followed for the development of tumors.  At approximately 15 weeks (Figure 30a) tumor 
development was observed in almost all of the treated TKp16L/Lp53L/L adult mice.  
Strikingly, the location on the skin where the hair was depilated and was treated with 4-
OHT is the area where tumors developed (Figure 28a).  In treated skin of the right flank 
in adult mice, levels of GFP, MitF and TRP2 expression were detected in melanocytes 
located in the hair follicles when compared to the left flank which was treated with  
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 Figure 28 
Adult mice develop tumors. A) Treated adult mice with TKp16L/Lp53L/L 
genotype developed tumors in area that was plucked.  Treated adult mice with 
either no KRas allele or TyrCreERT2 allele did not develop tumors in plucked area.  
B)  Imaging of tumors.  Tumors express the green fluorescent reporter allele.  
Areas that were treated of control mice did not express an elevated level of GFP; 
autoflourescence of hair follicles is seen.  Original magnifications 200X. 
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Figure 29 
Analysis of tumors generated from treatment of adult mice.  A) Analysis of 
treated skin from right flank showed an increase in GFP, Mitf and TRP2 expression 
when compared to untreated left flank.  B) Tumors from adult mice stained 
positively for TRP1, indicating a Melanocytic origin. 
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Figure 30 
Melanoma Kaplan-Meier survival analysis of tumors from adult mice.  A) Melanoma 
Kaplan-Meier survival analysis of treated adult mice with TKp16L/Lp53L/L genotype and 
treated adult mice with either no KRasallele or no TyrCreERT2 allele.  Differences between 
TKp16L/Lp53L/L and no KRas/Cre are statistically significantly (p < 0.0001).  B) Melanoma 
Kaplan-Meier survival analysis of treated adult mice with TKp16L/Lp53L/L genotype and 
treated pups with TKp16L/Lp53L/L genotype Differences between treated adult mice and 
treated pups is not significant (p= ns).   
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ethanol only (Figure 29a).  All tumors from adult treated mice stained positive for TRP1 
suggesting a melanocytic origin (Figure 29b).  There was a slightly significant difference 
in tumor latencies for TKp16L/Lp53L/L adult mice when compared to TKp16L/Lp53L/L 
neonates, suggesting the administration of 4-OHT to neonates is more tumorigenic due to 
its ability to be systemic and spread throughout the whole animal (Figure 30b).  To 
monitor melanoma development, a green fluorescent protein (GFP) reporter allele was 
crossed into the TKp16L/Lp53L/L model.  Through intravital confocal microscopy of 
TKp16L/Lp53L/L treated adult mice, CRE recombination and melanocytic origin was 
confirmed. While untreated skin has a base level of autoflourescence, all 
TKp16L/Lp53L/LGFPL/L tumors expressed GFP which allowed for visualization of 
individual tumor cells in vivo (Figure 28b). This is the first report of somatic 
development of melanoma in adult mice in vivo, suggesting the ‘development window’ 
for melanoma may be irrelevant and that the specific combinations of mutations of tumor 
suppressors and oncogenes are essential for melanocyte transformation.  
D.  Discussion  
We have provided evidence that somatic loss of p16Ink4a along with somatic 
activation of the Ras pathway can lead to melanoma development in vivo.  This work 
builds upon previous results based on melanoma mouse models that employ germline 
alleles.  Here we use conditional alleles and compare them to germline alleles to 
determine if somatically activating or deactivating alleles in melanocytes is more potent 
in their ability to transform melanocytes.  Surprisingly, we found that somatic 
inactivation of p16Ink4a generates a potent phenotype in melanocytes when compared to 
the somatic inactivation of p53.  While p16Ink4a is thought to be a powerful tumor 
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suppressor in humans, knockout alleles of p16Ink4a in the mouse have generated weak 
phenotypes suggesting that p16Ink4a is not important in tumor suppression in the mouse.  
However, here we employ a novel conditional allele of p16Ink4a and demonstrate that 
somatic deletion of p16Ink4a is a tumorigenic as somatic deletion of p53 which is 
strikingly different than germline knockout alleles of p16Ink4a and p53 (135, 136, 182).  
This provides genetic evidence that somatic deletion of p16Ink4a is more potent than 
germline deletion, suggesting that the use of the conditional allele should be considered 
when developing further mouse models of melanoma and testing therapies for the 
treatment of melanomas.   
Furthermore, the provocative finding that adult mammals could develop 
melanoma in vivo would argue against the idea that ultraviolet radiation-induced damage 
to melanocytes during development is important and damage later in life has a little to no 
effect (362).   Previous mouse models, demonstrated that only neonates were susceptible 
to melanoma after treatment with UVR, suggesting there is a ‘developmental window’ 
for melanocyte transformation to occur (317).  Here we test the ability of certain 
mutations to cause melanoma regardless of age and determined that adult mice along 
with young mice both develop melanoma, suggesting that the temporal relationship of 
damage is not the only requirement for tumor development but also the combinatorial 
affects of the mutations that occur.  The ability of sun exposure to induce carcinogenic 
affects may not be limited to a ‘development window’ but have the ability to induce 
melanoma at any age if it damages essential targets for melanocyte transformation.     
While, our work has demonstrated that conditional loss of p16Ink4a along with 
somatic activation of K-Ras cooperates to develop melanomas that are locally invasive 
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and necrotic, there was no evidence of metastasis in this model, suggesting other factors 
are involved in the dissemination of melanoma cells to distant tissues.  However, the 
rapid growth rate of the TKp16L/Lp53L/L could prevent metastasis because of early 
euthanization due to actual tumor size; therefore, insufficient time could be a potential 
reason why we could not detect metastasis in this model.  However, previous reports of a 
mouse model of melanoma using a melanocyte specific activated N-RasQ61K allele on an 
Ink4a/Arf deficient background generated metastatic melanomas, suggesting the Ras 
isoform could contribute to metastasis in melanoma (311).  This is in accordance with the 
result that activation of different Ras isoforms seems to be context dependent in 
melanocytes.  In a study using exogenous expression of either oncogenic K-RAS or N-
RAS in melanocytes, N-RAS enhanced MYC activity by repressing GSK3-mediated 
phosphorylation of MYC which contributed to both the increase in proliferation and the 
ability to grow in xenograft models (248).  Furthermore, other tumor suppressors or 
oncogenes might be necessary for metastasis.  Recently, to build a more faithful mouse 
model of melanoma which develops both pigmented and metastatic melanomas, a 
melanocyte specific CRE allele was crossed with an inducible B-RafV600E allele along 
with a conditional Pten allele.  The combination of B-RafV600E activation with Pten loss 
generated melanoma with high penetrance, short latency and metastasis to the lymph 
nodes and lungs (72).  In addition, the use of a conditional Lkb1 allele along with somatic 
activation of K-Ras in melanocytes generated both pigmented and metastatic melanomas 
in vivo (Monahan unpublished).  
We believe that generating genetically engineered mouse models of melanoma 
that are more representative of the human form of melanoma is the next step for pre-
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clnical screening of targeted therapies.  The use of conditional alleles will improve our 
understanding of melanoma and its resistance to traditional therapies.  Our study 
investigated the role of somatic loss both p16Ink4a and p53 along with somatic activation 
of K-Ras in the transformation of melanocytes.  Interestingly, the effects of p16Ink4a loss 
along with Ras activation developed melanoma in vivo.  Acute loss of p16INK4a and RAS 
activation are hallmarks of human melanoma, suggesting our model accurately 
recapitulates what occurs in human melanoma.  Furthermore, the observation that adult 
mice develop melanoma at a similar latency as young mice questions the belief that 
sunburn during childhood has a greater risk for melanoma development than sunburn 
later in adulthood.  Our findings suggest that a ‘development window’ does not exsist for 
tumor development and melanoma could result from acquired damage later in life.  Our 
faithful conditional model of melanoma is potentially a useful tool for the development of 
therapies for melanoma and to determine genetic factors that contribute to metastasis.   
E.  Materials and Methods 
 
Mouse colony and cell culture. Animals were generated and genotyped as previously 
described (313, 364, 365) and were N1 in B6. The p16 conditional allele was created by 
inserting a neo cassette in promoter region at the StyI site. The Neo cassette comprised of 
a left loxP site, a FRT site, neomycin resistance gene encoded by PGK promoter and an 
another FRT site. A Nhe I site was introduced next to StyI site. A Variable Number 
Tandem Microsatellite repeat sequence of approximately 560 bases was omitted 
immediately upstream of StyI site in the promoter region since it was proving difficult to 
clone the targeting vector with this sequence. The right loxP site was introduced next to 
XbaI site using newly created restriction sites NotI and XhoI. Homologous targeting of 
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the conditional allele was confirmed using southern blot for either side of arm. For left 
arm NheI enzyme (Endogenous allele produces 10.1 kb whereas targeted allele produces 
3.9 kb) was used and for Right arm XhoI enzyme was (Endogenous allele produces 6.6 
kb fragment and targeted allele produces 5.9 kb fragment) used. The mice thus generated 
were mated with Flpe mice (obtained from Jackson labortories) to excise neo fragment. 
To determine, p16Ink4a function in p16L/L mice, mouse embryonic fibroblasts (MEFs) 
were generated and treated with Cre recombinant adenovirus to induce recombination of 
the p16Inka conditional allele.  Mice were housed and treated in accordance with protocols 
approved by the institutional care and use committee for animal research at the University 
of North Carolina. Pups were treated with 4-hydroxytamoxifen (Sigma H7904-25MG) at 
25 mg/ml in DMSO starting at day 2 and were treated for three consecutive days (313). 
For adult mice, at 8 weeks of age, an area of fur was plucked and treated with 4-OHT.  
For survival analyses, animals were examined thrice per week. We assessed in vivo tumor 
growth rate by measuring the tumor areas (width X length).  Cell growth was normalized 
to day 1 values and analyzed using GraphPad Prism software (GraphPad Software Inc., 
La Jolla, CA).  Cell lines were generate and maintained as describe in (366).  For 
doxorubicin treatment, doxorubicin was diluted in DMSO at 300nm and cells were 
treated for 24 hour before harvesting. 
Western blots. Western blot assays were done on both tumor lysates and tumor cell 
lysates in RIPA buffer with protease inhibiots (Roche) and phosphatase inhibitors 
(Calbiochem) as described (ref). Antibodies against p21Cip1 (F-8, Santa Cruz), p16Ink4a 
(M-156, Santa Cruz), actin (C-1, Santa Cruz), cyclin D1 (DCS-6, Cell Signaling), cyclin 
E (M-20, Santa Cruz), cdk2 (M2, Santa Cruz),cdk4 (C-22, Santa Cruz) p15 (C-22, Santa 
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Cruz), p27(C-22, Santa Cruz), pp53 ( Cell Signaling) , p53 (CM5 novocastra), p-ERK 
(9101S Cell Signaling), ERK (9102 Cell Signaling), p-AKT (9271S Cell Signaling), 
AKT (9272 Cell Signaling), Bax (Santa Cruz), ARF (ab80 abcam) are commercially 
available.  
4-OH-Tamoxifen treatment of adult mice and Intravital Microscopy. Hair in both 
flanks of 50-55 days old mice was trimmed (1-2 cm2 square section) to prepare for 
treatment. One side was treated with 20 mM 4OH-T mol/cmμdissolved in ethanol (2 2 
skin) and the other side with 100% ethanol (control). The treatment was repeated the next 
day. At day 5 after treatment, mice were anesthetized with 2 % isofluorane and depilated 
by hand plucking the hair. For serial confocal imaging of tumors, mice were anesthetized 
with ketamine/xylazine and ear fur was removed using a commercially available 
chemical depilatory agent. GFP fluorescence in the ears was excited with 900-nm light 
from a Chameleon Ultra Ti-Sapphire pulsed laser (Coherent Inc., Santa Clara, CA) and 
imaged with a Zeiss LSM 510 NLO inverted 2-photon laser scanning microscope 
(Thornwood, NY) using 10x 0.3 NA, 20x 0.5 NA & 40x 1.2 NA (water-immersion) 
objectives. Images were captured using a 12-bit cooled CCD camera (Hamamatsu, 
Bridgewater, NJ).  
Immunohistochemistry. Assistance in sample processing was provided by the 
University of North Carolina Center for Gastrointestinal Biology and Disease.  At the 
time of experiment termination, ears, tumors, lungs, brains, spleens, kidneys and livers 
were fixed in 10% formalin, paraffin embedded, and cut into five-micrometer sections. 
Slides were deparaffinized and stained using a rabbit anti-TRP1, TRP2 (gift from Vincet 
Hearing) at a dilution of 1:500, with mouse Ki67 at a dilution of 1:100 or with mouse 
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GFP at a dilution of 1:500 with immunodetection by HRP or immunofloursecence after 
citric acid antigen retrieval.  Control samples were stained without primary antibody.  
Detection of antibody was done using highly sensitive DAKO EnVision polymerized 
horseradish peroxidase detection methods.  Epitope masking was performed using a 
mouse-on-mouse kit (Vector Laboratories, Burlingame, CA) per manufacturer’s 
instructions. Control samples were stained without primary antibody. Samples were 
visualized and photographed under bright field microscopy (Zeiss Axioskop 2, 
Thornwood, NY) using 10X 0.25 NA, 20X 0.50 NA and 40X 1.30 NA objective, and an 
Axiocam camera (Zeiss, Thornwood, NY).   
Statical analysis.  Tumor free surivial were analyazed using GraphPad Prism software 
(GraphPad Software Inc., La Jolla, CA) and comparisons were made using non-
parametric Mann-Whitney U-test.  Error bars +/- standard error of the mean. 
 
 
Table 8 Primers for screening 
Name  Primer sequence 
Lox GTP F GTATGCTATACGAAGTTATTAGGTACTGC 
Rcnt StySeqF GTTTTGGAGCAGCAGGGATT 
Rcnt StySeqR CTATGTCAGATTTGGCTAGGGAGT 
 
Table 9 Primers for detecting recombined p16INK4aL/L allele 
Name Primer sequence 
LtFRTSeqF TACCACAGTTTGAACAGCGTGA 
NewpKOlxlgR   AACCAACTTCCTCCTTCCCC 
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Chapter  
 V.  CD200 is induced by ERK and is novel therapeutic target in melanoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.  Abstract 
Immune-mediated, anti-tumor responses occur in patients with metastatic 
melanoma (MM), and therapies designed to augment such responses are clinically 
beneficial.  Despite the immunogenicity of melanoma, however, the majority of patients 
with MM fail immunomodulatory therapies. Inability of dendritic cells (DCs) to 
sufficiently activate effector cells may, in part, underlie this failure of the anti-tumor 
response seen in most patients.  In this work, we show that mutation of N-RAS or B-
RAF, signature genetic lesions present in most MM, potently induces the expression of 
cell-surface CD200, a repressor of DC function.   Employing two independent, genome-
wide microarray analyses, we identified CD200 as a highly dynamic, downstream target 
of RAS-RAF-MEK-ERK activation in melanoma.  CD200 protein was similarly 
overexpressed in melanoma cell lines and primary tumors. CD200 mRNA expression 
correlated with melanoma progression and was higher in melanoma than other solid 
tumors or acute leukemia.   Melanoma cell lines expressing endogenous CD200 repressed 
primary T-cell activation by DCs, and knockdown of CD200 by shRNA abrogated this 
immunosuppressive effect.  These data indicate that in addition to its effects on growth, 
survival and motility; ERK activation in MM attenuates a host, anti-tumor immune 
response, suggesting the CD200-CD200R interaction is a novel therapeutic target in MM. 
B.  Introduction   
Melanoma, the most lethal form of skin cancer, has increased in incidence and 
mortality over the last three decades.  Metastatic disease that is not amenable to surgery is 
generally refractory to therapy and therefore, ultimately lethal.  Standard chemotherapy 
typically produces response rates on the order of 10%, and radiotherapy plays only a 
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limited role in disease palliation.  Despite these sobering facts, some optimism has been 
engendered by recent advances in our molecular understanding of the disease, 
particularly the finding that ~80% of melanoma harbor mutually exclusive activating 
mutations of either N-RAS or B-RAF (reviewed in (368)).  These lesions lead to 
activation of the RAF>MEK>ERK MAP kinase pathway, which in turn controls the 
transcription of hundreds if not thousands of genes related to cellular proliferation, 
survival and motility (264).  Although work in murine models and pharmacological 
approaches have suggested that RAS-RAF activation is required not only for tumor 
formation, but also for tumor maintenance (249, 369), the cell biological effects of ERK 
activation that are most relevant for tumor formation and progression have not been fully 
established.   
 Arguably, the evidence for a clinically valuable, anti-cancer immune response is 
stronger in melanoma than any other human malignancy (reviewed in (370-373)).   
Functional T-cells restricted to melanoma antigens can be readily recovered from patients 
with melanoma, establishing the tumor’s immunogenicity in humans (370, 372-374).  
Anecdotal spontaneous remissions, thought to be immune-mediated, have been described 
by multiple investigators, and the appearance of vitiligo, an autoimmune response to 
melanocytes, is of good prognostic significance in patients with melanoma (375-377).  
Therapeutic strategies to augment the immune response, e.g. interferon and IL-2, 
demonstrate efficacy in certain clinical settings (370, 371, 373, 378)  and anti-CTLA4 
antibodies, which enhance T-cell activation, have been reported to possess promising 
single agent activity in early clinical trials (35, 379).  Despite these findings, however, the 
majority of patients with melanoma eventually fail immunotherapeutic approaches and 
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succumb to progressive disease.  In particular, antigen presenting cells, especially 
dendritic cells (DCs), appear unable to sufficiently augment the anti-melanoma response 
for effective tumor clearance.  Melanoma cell lines have been reported to repress DC 
function through the elaboration of soluble factors and by direct physical interaction 
(331, 380-382).  These observations have in turn motivated clinical strategies to augment 
DC function in melanoma in order to enhance anti-tumor immunity (383, 384).    
 Given this background, we considered our recent finding, through an unbiased 
genomic approach, that CD200 correlates with ERK activation in melanoma particularly 
provocative (264).  CD200, initially described as the Ox-2 tumor antigen, is a type I 
membrane-associated glycoprotein and a member of the immunoglobulin super family 
(334).  It is expressed on a variety of cell types; including myeloid cells, endothelium, 
ovarian cells, placental trophoblasts and neurons.  Recent work has shown that CD200 
induces an inhibitory signal by interacting with CD200 receptors (CD200R) expressed on 
myeloid cells, particularly macrophages and DCs (337, 343, 345).  This interaction 
generates signals that negatively regulate immune and inflammatory responses and which 
prevent an autoimmune response in a number of systems (342, 343, 347, 385, 386).  
Moreover, a few phylogenetically distinct viruses including Pox viruses and KSHV, the 
causative agent of Kapsosi’s sarcoma and other human cancers, have been shown to 
attenuate the host antiviral immune response by expressing a viral CD200-homologue 
(341, 387-389).  Given the storied history of host-gene homologues in the ability of DNA 
tumor viruses to promote cancer (e.g.(390-392)), we considered this latter finding 
particularly compelling.  Therefore, although 81 other ERK targets including several of 
likely pathogenic significance (e.g. IL-8, TWIST1, FGF2, CXCL1/GRO1) were 
110 
 
identified in our genomic screen, these facts motivated more detailed study of CD200 in 
particular.  In this work, we show that CD200 mRNA and protein is regulated by ERK 
activation, and CD200 is expressed in the majority of melanoma but only rarely in other 
solid tumors. Moreover, this expression is immunologically significant, as endogenous 
levels of CD200 on melanoma cell lines attenuate the ability of DC’s to activate T-cells 
in a mixed lymphocyte reaction.  As blocking antibodies to CD200 are in pre-clinical 
development, these observations suggest that the CD200-CD200R interaction is a 
therapeutic target in melanoma 
C.  Results 
CD200 is regulated by N-RAS>B-RAF>MEK>ERK MAP Kinase pathway  
Through the manipulation of ERK signaling in melanoma cell lines, we recently 
demonstrated in two independent microarray screens that CD200 mRNA expression in 
melanoma is regulated by the N-RAS>B-RAF>MEK>ERK pathway (264).  The pattern 
of CD200 expression in melanoma cell lines was similar to that of other known ERK-
targets such as IL-8. and SPRY2:  low in normal melanocytes and melanoma cells lines 
with low pERK; high in cell lines with high expression of pERK and inhibited by U0126, 
a potent MEK inhibitor (Figure 31a).  By TaqMan RT-PCR, we showed a significant 
reduction in CD200 in 2 melanoma cell lines with high baseline pERK (WM2664 and 
SKMEL24) after as little as 4 hours of treatment with UO126, a pharmacologic inhibitor 
of MEK (Figure 31b).  In addition, melanoma cell lines WM2664, SKMEL24 and 
SKMEL28 transduced with a BRAF knockdown, showed a significant reduction in 
CD200 expression 4 days after transduction (Figure 32a, b).  Analysis of a panel of 
melanoma cell lines with high levels of pERK showed a >10-fold increase of CD200 
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protein expression by flow cytometry when compared with melanoma cells with low or 
absent pERK (Figure 31c,d).  These data show that CD200 mRNA and protein are 
dynamic and highly expressed ERK-targets in melanoma cell lines.   
CD200 is highly expressed on melanomas. 
To support these observations, the expression of CD200 mRNA and protein was 
tested in groups of resected human tumors.  Using a newly developed method to perform 
expression analysis on RNA derived from formalin-fixed paraffin-embedded (FFPE) 
samples (393), we extracted RNA of sufficient quality for microarray analysis from 20 
solid tumors including 6 melanoma metastases, 5 breast cancers, 8 colon cancers and one 
lung adenocarcinoma. Through this approach, CD200 was found to be highly expressed 
in melanomas compared to other solid tumors, which have low or absent expression of 
CD200 (Figure 33a).  Furthermore, CD200 expression strongly correlated in 
unsupervised hierarchical clustering with other melanoma signature transcripts such as 
MitF, endothelin receptor type B and silver homolog.  These results were independently 
confirmed in publicly available microarray datasets analyzing the NCI60 cell lines (394) 
and primary human melanocytic lesions (395) (Figure 34a).  In the later dataset from 
Haqq and colleagues, CD200 expression was increased in melanocytic lesions and 
correlated with progression from nevi to melanoma (Figure 34b) in accord with our 
demonstration that CD200 is regulated by pERK.  In the NCI60 dataset, mRNA levels 
were uniformly higher in melanoma than any other tumor type including the 8 
representative leukemia cell lines (Figure 34a).  In aggregate, these data confirm that 
CD200 mRNA is highly and uniformly expressed in the majority of primary melanoma, 
but only rarely in other solid tumors.  
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Figure 31 
CD200 is a p-ERK target in melanoma.  A) Dendogram of melanoma specific transcripts 
that are regulated by p-ERK expression in indicated melanoma cell lines.  Melanoma cell 
lines with high levels of activated ERK (black) show increased CD200 expression.  
Melanoma cell lines with low ERK activity lacking RAS/RAF mutation (blue) or treated 
with UO126 (a MEK inhibitor, green) and normal human melanocytes (red) have low 
expression of CD200 and other known ERK targets.  B) Taqman qRT-PCR of CD200 
expression after U0126 treatment of human melanoma cell lines. WM2664 and SKMEL24 
cell lines were treated with U0126 for 4, 8, and 24hrs.  CD200 expression was normalized to 
a control transcript (18S).  Error bars are +/- the standard error of the mean (SEM).  * = 
p<0.05. C)  Immunoblot showing ERK activation in melanoma cell lines. Protein lysates 
from the indicated melanoma cell lines were immunoblotted with anti-phospho-ERK and 
anti-total ERK.  D)  Flow cytometry was performed on melanoma cell lines WM2664, 
SKMEL24 and SKMEL28 (high p-ERK) and melanoma cell lines PMWK, MEL505 and 
SKMEL187 (low p-ERK).  The high p-ERK lines express high levels of CD200, while low 
p-ERK lines express low levels of CD200.  
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Figure 32 
 
 
 
 
BRAF regulates CD200 expression in melanoma cell lines.  A) Taqman qRT-PCR of 
CD200 expression after WM2664, SKMEL24, and SKMEL28 melanoma cell lines were 
transduced with a BRAF knockdown construct.  CD200 expression was normalized to a 
control transcript (18S). B) Western blot analysis of p-ERK, ERK and BRAF after 
WM2664 cells are transduced with BRAF knockdown. 
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 To confirm these results at the level of protein, we developed an 
immunohistochemical strategy to detect CD200 on FFPE samples.  Upon validation of 
our IHC approach on known CD200-expressing tissues, placenta and thymus, we turned 
to the analysis of normal skin and 57 resected melanocytic lesions including benign and 
dysplastic nevi, primary melanomas, and melanoma metastases (Figure 33b).  In accord 
with the in vitro results (Figure 31a), no CD200 expression of quiescent melanocytes 
Table 10  CD200 expression in melanocytic lesions by IHC 
Lesion CD200 staining (medium to high) 
Nevi  27 of 34 (79%) 
Melanoma 11 of 23 (48%) 
Total 38 of 57 (67%) 
residing in normal skin was detected (Figure 5-3b  In contrast, however, there was 
marked expression in the majority of nevi and melanomas (Figure 33b and Table 10).  
Although CD200 is an ERK-target in vitro and CD200 mRNA expression correlates with 
progression, CD200 expression did not correlate with pERK staining in melanocytic 
lesions by IHC.  In particular, CD200 expression was found throughout the entire 
spectrum of melanocytic neoplasms (Table 10), including nevi, whereas pERK 
expression was more frequent in later stage lesions (not shown).   Several possible 
explanations could reconcile these findings:  immunohistochemical analysis of pERK and 
CD200 is at best semi-quantitative and not as reliable as RNA analysis, factors in 
addition to pERK likely regulate CD200 expression in nevi, or the increased proliferative 
rates of melanomas compared to nevi may dilute the protein expression of this stable cell 
surface molecule.  These concerns notwithstanding, these IHC analyses demonstrate 
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 Figure 33 
CD200 is expressed on melanoma.  A) Dendogram of select melanoma associated 
transcripts. CD200 expression correlates with other well-established melanoma transcripts 
(MitF, DCT, SILV, EDNRB).  CD200 expression is low or absent in colon and most breast 
cancers.  SKMEL24 human melanoma cell line is used as control.  B) Immunohistochemistry 
for CD200 was performed on a series of normal skin, nevi and melanomas (primary and 
metastases).  Normal skin and melanocytes do not show CD200 expression, while the majority 
of nevi and melanomas strongly express CD200.  Placenta is shown as a positive control, 
original magnification, 200X. 
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 Figure 34 
CD200 expression on melanoma cell lines and in stages of melanoma.   A)  CD200 
expression in NIC60 cell lines.  Source data is described in Ross et al, Nature Genetics 2000 
(38).  Note the markedly increased expression of CD200 in the melanoma cluster, with an 
expression pattern comparable to established melanoma transcripts (CD200 clustered 
closely with ENDRB and DCT in this data set and the set of primary tumors shown below).  
B)  CD200 expression was analyzed in source data from Haqq et al. PNAS 2005 (39).  In 
this independent data set of melanocytic lesions, CD200 expression correlated with tumor 
progression.   
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 increased expression of CD200 protein in the majority of human melanocytic neoplasms.   
 CD200 is required for inhibition of T cell activation. 
In order to determine the functional importance of CD200 expression on 
melanoma cell lines, we sought to evaluate the generation of proinflammatory cytokines 
induced during a mixed lymphocyte response in the presence of melanoma cells with and 
without physiological levels of cell surface CD200.  Although CD200 mRNA rapidly 
plummeted with UO126 treatment (Figure 31b), no change was seen in the expression of 
CD200 on the cell surface even after 48 hrs of UO126 treatment (data not shown), 
suggesting the cell surface fraction is highly stable.  More prolonged treatment of cell 
lines with U0126 was not possible because of toxicity.  In order to modulate CD200 
expression in melanoma cells, we generated a short hairpin RNA construct specifically 
targeting the human CD200 ligand.  shRNA oligonucleotides were cloned into a lentiviral 
transduction vector that also harbors EGFP driven by the CMV promoter.  Therefore, 
melanoma cells transduced with the CD200 shRNA knockdown construct express GFP 
(Figure 35a).  Maximal knockdown of human CD200 (>6.5 fold by flow, Figure 35b) 
required six or more passages after transduction (>15 days post-transduction, Figure 
35b), suggesting that the membrane-associated fraction is stable and predominantly 
decreased on the cell surface by dilution with proliferation.  CD200 knockdown did not 
alter the in vitro growth or survival of melanoma cell lines.  After transduction and serial 
passage, transduced cells were flow-sorted by GFP to produce cell lines that differed only 
in their expression of CD200 (Figure 35c). In order to control for potential effects of 
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shRNA-mediated knockdown of CD200 expression.  A)  WM2664 human melanoma cells 
were transduced with a GFP expressing human CD200 shRNA construct and stained with an 
anti-human CD200 antibody (red). Untransduced WM2664 cells express CD200 (red).  
Transduced WM2664 cells are negative for CD200 expression. Nuclei of cells are stained with 
DAPI seen in blue. B)  CD200 expression at different passages in culture post-transduction was 
analyzed by flow cytometry. Efficient knockdown of the CD200 protein was observed after 6 
passages (>15 days) in culture.   C)  WM2664 human melanoma cells were FACS sorted for 
GFP expression and then analyzed by immunofluorescence for CD200 expression.  WM2664 
cells transduced with a CD200 shRNA are negative for CD200 expression.  WM2664 cells 
transduced with a non-specific shRNA showed high staining for CD200 (red).   
Figure 35 
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RNA interference, melanoma cell lines were also transduced with a non-specific short 
RNA hairpin, which did not alter the levels of CD200 expression (Figure 35c).  
To investigate the functional importance with regard to the immune response of 
CD200 expression on melanoma cell lines, cytokine production during a mixed 
lymphocyte reaction (MLR) was evaluated with the addition of irradiated melanoma cell 
lines with varying CD200 expression levels.  When human melanoma cell lines 
WM2664, SKMEL24, and SKMEL28, which harbor high pERK and CD200 expression, 
were added in a MLR, an inhibitory effect on T cell activation by DCs was noted as 
evidenced by a significant decrease in IL-2 and IFN-γ levels (Figure 36a, 37b).  In 
contrast, IL-2 and to a lesser extent IFN-γ production, was augmented when MLRs were 
performed in the presence of human melanoma cell lines PMWK, Mel505, and 
SKMEL187 which harbor low pERK and CD200 expression (Figure 31c, 37b).   
As many factors besides CD200 expression differed among these cell lines, we 
conducted MLRs with high CD200-expressing melanoma cell lines WM2664, 
SKMEL24, SKMEL28 in which the expression of CD200 was decreased by shRNA 
knockdown (WMKD, SK24KD, SK28KD respectively).  Inhibition of CD200 expression 
significantly impaired the ability of these cell lines to inhibit T cell proliferation when 
compared to the parental cell lines.  In the presence of human melanoma cells transduced 
with CD200-knockdown shRNA, DC-activated lymphocytes produced increased levels  
of IL-2 and IFN-γ at 72 hours when compared to the parental cell lines or cells 
transduced with non-specific short hairpin RNA (WMNS, SK24NS, SK28NS; Figure 
36b, 37b).   A comparable inhibition of T-cell rosetting was associated with decreased  
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 Figure 36 
 
 
 
 
 
 
 
 
CD200 is required for T Cell Repression.  A)  IL-2 production by T lymphocytes during mixed 
lymphocytic reactions (MLRs) with the addition of human melanoma cell lines with varying levels of 
CD200 expression. WM2664, SKMEL24, and SKMEL28 express high levels of CD200; PMWK, 
MEL505, and SKMEL187 express low levels of CD200.  IL-2 production, as a marker of T cell 
activation, was determined by ELISA after 72 hours of incubation.  Indicated statistical comparisons 
are between the indicated cell line versus T-cell + dendritic cells only (***=p<0.0001; **=p<0.005). 
Error bars are +/- the standard error of the mean (SEM).  B)  MLRs in the presence of WM2664, 
SKMEL24 and SKMEL28 transduced with non-specific hairpin (WMNS, SK24NS, SK28NS) and 
WM2664, SKMEL24 and SKMEL28 transduced with CD200 knockdown (WMKD, SK24KD, 
SK28KD).  Dendritic cells and T cells were mixed with indicated human melanoma cell lines +/- 
CD200 shRNA knockdown. IL-2 production was significantly higher in CD200 knockdown 
melanoma cell lines (WMKD, SK24KD, SK28KD) when compared to the parental melanoma cell 
lines transduced with a non-specific shRNA (WMNS, SK24NS and SK28NS). Error bars +/- SEM.  C)  
Quantification of T cell rosettes. WMKD and SK24KD show a significant increase in the formation of 
T cell rosettes when compared to their parental cell lines transduced with a non-specific shRNA in 
MLRs.  A mix of T cells + DC was used as a positive control (first panel). Error bars +/- SEM.  D)  
WMKD and SK24KD show a significant increase in the formation of T cell rosettes when compared 
to their parental cell lines transduced with a non-specific shRNA in MLRs.  A mix of T cells + DC 
was used as a positive control (first panel).  Original magnification, 100X. 
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 Figure 37 
 
 
 
 
 
 
 
 
 
CD200 is required for T Cell Repression and IFN-γ production.  A) WM2664 and SKMEL24 
(high CD200) show an increase in the formation of T cell rosettes when compared to PMWK and 
MEL505 (low CD200) in MLRs.  A mix of T cells + DC was used as a positive control (first 
panel). B)  IFN-γ production by T lymphocytes during MLRs with the addition of human 
melanoma cell lines with varying levels of CD200 expression. WM2664, SKMEL24, and 
SKMEL28 express high levels of CD200; PMWK, MEL505, and SKMEL187 express low levels 
of CD200.  IFN-γ production, a marker of T cell activation, was determined by ELISA after 72 
hours of incubation. C)  MLRs in the presence of WM2664, SKMEL24 and SKMEL28 transduced 
with non-specific hairpin (WMNS, SK24NS, SK28NS) and WM2664, SKMEL24 and SKMEL28 
transduced with CD200 knockdown (WMKD, SK24KD, SK28KD).  Dendritic cells and T cells 
were mixed with indicated human melanoma cell lines +/- CD200 shRNA knockdown.  IFN-γ 
production was significantly higher in CD200 knockdown melanoma cell lines (WMKD, 
SK24KD, SK28KD) when compared to the isogenic lines transduced with a non-specific shRNA 
(WMNS, SK24NS and SK28NS). Error bars +/- standard error of the mean (SEM), results 
represent three independent experiments.  D)  Quantification of T cell rosettes, WM2664 and 
SKMEL24 show a significant increase in the formation of T cell rosettes when compared to 
PMWK and Mel505 (**=p<0.005; *=p<0.05).  Error bars +/- standard error of the mean (SEM). 
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CD200 expression across the panel of cell lines and with CD200 knockdown (Figure 
36c,d, 37a,d) in the MLRs.  Therefore, physiological expression of CD200 on the cell 
surface of melanoma cell lines attenuates the ability of DCs to activate T cells. 
D.  Discussion  
In this work, we have shown that CD200 mRNA and protein expression is 
regulated by ERK activation, a signaling event required in the majority of melanoma for 
progression and maintenance. Through an analysis of CD200 mRNA and protein 
expression in FFPE tumors, coupled with comparison of two independent publicly 
available melanoma microarray datasets, we have shown that expression of CD200 
correlates with disease progression and appears more abundant in melanoma than any 
other common solid tumor or acute leukemia.  Finally, we have shown that the 
endogenous CD200 expression on melanoma cell lines represses the ability of dendritic 
cells to activate primary T-cells in MLRs, and that this effect is largely abolished by 
shRNA-mediated knockdown of CD200 in these lines.  Therefore, the induction of 
CD200 by ERK activation appears to decrease tumor immunogenicity in melanoma.   
Recent studies relying, like the present work, on unbiased, genome-wide analyses 
have suggested that CD200 expression may play a role in the pathogenesis of B-cell 
lineage malignancies and acute leukemia.  Moreaux et al. showed that increased CD200 
mRNA expression by microarray correlated with reduced event-free survival (22 months 
vs. 14 months) in patients with myeloma (352).  The effect of CD200 on prognosis was 
independent of known adverse prognostic factors in myeloma, suggesting CD200 
expression per se was pathogenic.  A similar result was seen by Tonks et al. in acute 
myeloid leukemia (353).  McWhirter et al. showed increased CD200 expression in CLL 
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samples relative to normal B-cells.  In accord with our findings, the authors also showed 
that CD200-expression is associated with decreased CLL cell immunogencity in a MLR 
(351).  This effect could be partially blocked by incubation of the CLL cells with anti-
CD200 antibodies, concordant with results seen using CD200 shRNA.  In aggregate, 
these data suggest a pathogenic role of CD200 expression in certain hematologic 
malignancies.   
We have extended these results to melanoma, an important human solid tumor for 
which ample evidence suggests there is a clinically beneficial anti-tumor immune 
response in some patients.  In the NCI60 cell line data set, as well as FFPE samples, 
CD200 expression was higher and more ubiquitous in melanoma compared to other solid 
tumors.  It is worth noting, however, that increased CD200 expression was also detected 
in a small subset of samples of other solid tumors such as breast, ovarian and lung 
cancers (see Fig. 2a and Supp. Fig 2a).  Therefore, CD200 expression may play a role in 
the disease pathogenesis of subsets of other solid tumors as well. 
We believe these findings have important and direct clinical relevance to the 
treatment of melanoma.   For example, while there is some enthusiasm in melanoma to 
combine novel RAF and MEK inhibitors, which inhibit proliferation, with classical 
chemotherapeutic agents, which target cycling cells; our data suggest the combination of 
such targeted kinase inhibitors with immunomodulatory agents such as IL-2 or IFN is at 
least as rational a strategy.  Moreover, as at least one CD200 blocking antibody is in pre-
clinical development for cancer therapy (Alexion Pharmaceuticals), this work has 
important implications for the development of anti-cancer therapies to target directly the 
CD200-CD200R interaction.  In comparison to blocking antibodies against CTLA4 
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which have shown promising single-agent activity in melanoma, it is important to note 
that response to anti-CTLA4 seems to correlate with the development of significant 
immune enterocolitis (379).  Patients who had the most severe autoimmune stigmata 
appeared to derive the greatest benefit from CTLA4 blockade.  In this regard, it is 
encouraging to note that the CD200 knockout mice demonstrate a much less severe 
autoimmune phenotype than CTLA-4-deficient mice (343, 396, 397), suggesting 
blockade of CD200 blockade will be better tolerated than that of CTLA4.  Lastly, we 
believe these data suggest that melanoma is perhaps the best candidate disease for the 
testing and development of anti-CD200 approaches.  In particular, patients with 
melanoma who are candidates for Phase I therapies are not rare and tend to be younger, 
less heavily pre-treated and of better performance status than patients with refractory 
hematologic malignancies, who are uncommon and generally heavily pre-treated prior to 
consideration for a Phase I trial.  Therefore, we believe this identification of melanoma as 
a rational target disease will facilitate the development of CD200-CD200R anti-cancer 
therapies. 
E. Materials and Methods 
Cell lines.  Human melanoma cell lines WM2664 and PMWK were obtained from J 
Arbiser, Mel505 was obtained from J. Hansson, SKMEL187 was obtained from A. 
Houghton and SKMEL24, SKMEL28, and 293FT were obtained from ATCC and 
cultured in either DMEM with the addition of 10% fetal bovine serum and 
penicillin/streptomycin (WM2664, 293FT, PMWK, SKMEL187), MEM- with the 
addition of 10% Non-essential Amino Acids and 10%FBS, and penicillin/streptomycin 
(SKMEL24, SKMEL28), or RPMI with addition of 10%FBS and penicillin/streptomycin 
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(Mel505) (Gibco, Grand Island, NY) .  Human melanoma cell lines, WM2664, 
SKMEL24, SKMEL28, SKMEL187 and Mel505, were derived from vertical growth 
phase melanomas and human melanoma cell line PMWK was derived from a radial 
growth phase melanoma.  Cells were incubated at 37C, 5%CO2, and media was changed 
every other day. Subconfluent cells were trypsinized and replated at the appropriate 
densities.  Human dendritic cells were differentiated from CD34+-selection (Miltenyi 
Biotec, Auburn, CA) following a 15L apheresis collection of peripheral blood (Cobe-
Spectra, GambroBCT, Lakewood,  CO).  DCs were expanded first in the presence of 
GM-CSF(Immunex, Seattle WA, USA), FLT3-ligand, IL-4, stem cell factor, and TNF-a 
(Peprotech, Rocky Hill, NJ, USA) using AIM-V media (Gibco, Grand Island, NY) with 
10% human AB serum (Gemini Bio-Products West Sacramento, CA).  Microarray 
analysis, TaqMan analysis, ERK western analysis and ERK inhibition with UO126 of 
melanoma cell lines were performed as described (356).   
Mixed lymphocytic reactions.  Mixed lymphocytic reactions were set up in 12-well 
plates by using 100,000 dendritic cells and 2 X 106 T cells.  T cells were enriched by 
incubating the cells for 2 hrs in tissue culture flasks and taking the non-adherent cell 
fraction.  Irradiated melanoma cell lines (250,000 per reaction) were added to the mixed 
lymphocytic reactions at the start of the experiment, and supernatants were collected after 
72 hrs and analyzed for the presence of IL-2 and IFN-.  
IL-2 and IFN-γ ELISA.  Conditioned media was obtained from mixed lymphocytic 
reactions and assayed for the presence of IL-2 and IFN- by ELISA following the 
manufacture’s instructions (Quantikine Kit, R&D Systems, Minneapolis, MN). OD 
measurements were performed using a Kinetic Microplate Reader (Molecular Devices, 
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Sunnyvale, CA). T cells plus dendritic cells in the absence of melanoma cells and 
melanoma cells alone (not shown) were used as controls. 
 DNA constructs, viral production and infection of target cells. shRNA coding 
oligonucleotides were designed and verified to be specific for Human CD200 according 
to BLAST search against human genome.  Human CD200 shRNA targeting sequence: 
TGGTAATTCTTCTCGTCCTGTTCAAGAGATAGGACGAGAAGAATTACCTTTTT
TTTC.  The insert was cloned between the Xho-1 and Hpa-1 and sites of the pLentiLox 
3.7 vector. A non specific shRNA construct was used as control. The production of 
lentiviruses in 293 FT cells and infection of target cells was as described previously 
(398).  WM2664 and SKMEL24 cells were infected with the viral supernatant, and 
CD200 expression levels were analyzed and positive cells were sorted by flow cytometry.  
BRAF mutant shRNA (pSuper) plasmid,  as previously described in (399) was added to 
293 FT cells for the production of retrovirus.  WM2664, SKMEL24 and SKMEL28 cells 
were infected with viral supernatant for 24 hours and cells were selected in media contain 
5μg/mL Puromycin for 4-5 days and CD200 expression levels were analyzed by Taqman 
qRT-PCR. 
Flow Cytometry.   Exponentially growing cells were detached using 0.5 mM EDTA for 
3-5 min at 37°C and stained with fluorescein isothiocyanate (FITC)-conjugated 
antibodies to the CD200 surface antigen (MCA1958FA, Serotec, Raleigh, NC) analyzed 
using a FACScan analytical flow cytometer (Becton-Dickinson Immunocytometry 
Systems, San Jose, CA).  Appropriately gated cells were analyzed (10,000 cells counted 
per staining) and compared to unstained or isotype controls.   
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Indirect immunofluorescence analysis and image acquisition.  Cells were plated on 
glass coverslips and fixed with 4% PFA. After washing and blocking with PBS+10% 
FBS, cells were stained with mouse anti- human CD200 antibody (R&D Systems, 
Minneapolis, MN, 1:100 dilution), followed by incubation with 594AlexaFluor-conjugated 
goat anti-mouse secondary antibody (Neomarkers, Fremont, CA).  Cell-containing 
coverslips were mounted onto glass slides and nuclei were counterstained using DAPI-
Vectashield. Cells were visualized and photographed using a fluorescence microscope 
(Olympus model IX-81) equipped with a X60 1.45 NA objective, a CCD camera (model 
C4742-80-12AG, Hamamatsu) and controlled by AQM Advanced 6 software (Kinetic 
Imaging, LTD). 
RNA analysis and IHC on nevi and melanomas. RNA from formalin-fixed and 
paraffin embedded tumors samples of 2-8 years of age was prepared using a 
commercially available FFPE extraction kit (Arcturus), and amplified and labeled as 
described (400).  Amplified RNA from tumors was hybridized to the Agilent 22K 3’-
biased arrays and analyzed by unsupervised hierarchical clustering.  An excerpted cluster 
of this analysis is shown in Figure 2a.  See (400) for details and primary data, all primary 
microarray data can be downloaded from the UNC microarray database genome.unc.edu.  
The study was approved by the Institutional Review Board of the University of 
North Carolina.   The tissues used in this study were selected at random from a series of 
cases treated at UNC Hospitals after 2000.  All cases, including 23 melanomas and 34 
benign nevi, underwent standardized histopathology review of hematoxylin and eosin 
stained sections of the specimens for confirmation of diagnosis and evaluation of lesional 
characteristics.  5 micron sections were deparaffinized and stained using a commercially 
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available CD200 antibody (R&D, AF2724) at a dilution of 1:50 with immunodetection 
by HRP after Tris-EDTA antigen retrieval.  Staining was validated on control tissues 
(placenta and thymus) consistent with the known pattern of expression of CD200 in these 
organs. All tissues were scored for staining intensity by two pathologists (DZ, PG) for 
localization, percentage of cells, and intensity of staining.  For the majority of nevi and 
melanomas, more than 50% of the cells stained with the CD200 antibody.  The CD200 
localization was cytoplasmic or both cytoplasmic and membranous. The intensity was 
scored as none, low, medium, or high and dichotomized as none to low versus medium to 
high for the purposes of this paper. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
129 
 
Chapter  
VI.  Conclusions and Future Directions
 
The studies presented in this thesis aimed at evaluating the use of conditional 
alleles in genetically engineered mouse models of melanoma and determining factors that 
influence the immune response in melanoma patients.  Through the use of genetically 
engineered mouse models of melanoma we have been able to filter out some of the 
complexity in melanoma.  Mouse models have many advantages ranging from 
determining genetic factors and evaluating drug efficacies; however many current mouse 
models of melanoma employ constitutively active transgenes along with germline 
knockout alleles.  To date, conditional alleles have not been used in genetically 
engineered mouse models of melanoma.  This work addresses this issue and determines if 
the use of conditional alleles have different effects on melanocytic transformation than 
germline alleles.  The development of a melanocyte-specific inducible CRE allele (Tyr-
CRE-ERT2) has allowed us to conditionally regulate gene expression strictly in mouse 
melanocytes (313).    We first examined the role of somatic inactivation of both p16Ink4a 
and p53 along with somatic Ras activation in the transformation of melanocytes.  
Surprisingly, all combinations of conditional alleles TKp16Ink4a+/+p53+/+, TKp16 L/L 
p53L/L, TKp16L/L and TKp53L/L generated melanoma in vivo, suggesting that conditionally 
inactivating or activating certain genes is potently tumorigenic.   Furthermore, the lack of 
metastasis in this model questions the role of p16Ink4a, p53 and K-Ras in melanoma 
metastases and suggests that other tumor suppressors and/or oncogenes are involved in 
metastasis.   
In addition to generating a novel conditional mouse model of melanoma, previous 
studies evaluating novel ERK targets in melanoma identified CD200 as a potential player 
in the evasion of the immune system.  In chapter 5, we examined the role of CD200 in the 
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immune system through its inactivation in human melanoma cell lines by transduction 
with a CD200 shRNA lentiviral construct and evaluated these cells’ capacity to induce 
specific cytokine production in mixed lymphocytic reactions.  This study determined that 
CD200 has a causal role in regulating the immune system; however the mechanism by 
which CD200 and CD200R transmit their negative immune response signal and its 
therapeutic potential are still largely unknown.  
A. Loss of p16INK4a, p53 and somatic activation of K-Ras in melanocytes 
 The role of the INK4a/ARF tumor suppressor locus in melanoma is unequivocal.  
However, the individual contributions of each tumor suppressor protein: p16INK4a and 
ARF is still undetermined. To elucidate the role of p16INK4a in melanocytes a novel 
conditional allele of p16Ink4a was crossed to a p53Flox allele, K-RasG12D allele and a 
melanocyte-specific inducible CRE allele (Tyr-CRE-ERT2).  TKp16L/Lp53L/L mice treated 
with 4-OHT generated melanomas within 8-14 weeks and were locally invasive and 
highly vascular.  Surprisingly, after treatment with 4-OHT, TKp16L/L mice developed 
tumors within 24 weeks while TKp53L/L mice developed tumors within 31 weeks.  While 
this difference is not significant, the observation that the somatic loss of p16Ink4a was as 
tumorigenic as somatic loss of p53 is strikingly different than the outcomes of germline 
deficient alleles for either p16Ink4a or p53. p53 deficient mice are highly tumor prone 
whereas p16Ink4a deficient mice have a weak phenotype. Furthermore, the outcome 
resulting from somatic deletion of p16Ink4a along with somatic activation of K-Ras in 
melanocytes is dramatically different than p16Ink4a homozygous germline deletion in the 
Tyr:HRasV12G model which moderately develops tumors at 75 weeks.  This difference 
could be explained by different RAS isoforms playing diverse roles in melanoma 
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development; however, western blot analysis of various RAS targets showed no 
differences between the two mouse models. These results suggest that the somatic 
deletion of p16Ink4a versus germline deletion of p16Ink4a in the context of melanocytes has 
a strikingly different effect and is more potently tumorigenic. These results support the 
role of somatic deletion of p16Ink4a in melanoma and mimic what is seen in human 
melanoma, with p16INK4a mutations being highly prevalent in specific types of sporadic 
human cancers. 
It is worth noting that in order to define the role of the Arf-p53 pathway, we used 
a readily accessible p53 conditional allele; however the role of p53 mutation in 
melanoma has not been established and is inconsistent, whereas Arf has been suggested 
to play a role in melanoma suppression.  To accurately determine the Arf-p53 pathway in 
melanoma, the function of Arf needs to be studied.   Arf has been shown to have p53-
independent function in melanocytes suggesting that stabilizing p53 is not the only way 
ARF functions to suppress melanoma (163).  For future studies, using an ARF 
conditional allele will decipher the effects of somatic loss of p16INK4a versus ARF in 
melanoma and determined the individual contributions of each tumor suppressor in 
melanocyte transformation. 
B.  Loss of p16Ink4a, p53 and activation of K-Ras are not required for metastasis 
While the cooperation of somatic loss of p16Ink4a and K-Ras activation in mouse 
melanocytes develops a new conditional mouse model of melanoma which is similar to 
human melanoma, there was no evidence of metastasis in this model suggesting other 
factors are involved in metastasis in melanoma. One potential drawback of the 
TKp16L/Lp53L/L melanoma model is the use of the K-RasG12D allele.  In human melanoma 
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N-RAS and B-RAF are mutated in approximately 20% and 70% of melanomas 
respectively, while K-RAS is activated in about 3% of melanomas, suggesting that N-
RAS and B-RAF activation are specific for melanocyte transformation (15, 246).  
Recently, a mouse model of colon cancer using different conditional Ras alleles: K-
RasG12D and N-RasG12D demonstrated that K-Ras activation stimulated colonic epithelium 
hyperproliferation, while N-Ras activation had little effect, confirming that Ras isoforms 
have different phenotypic function in specific cell types (401).  Furthermore the 
expression of constitutively active HRAS in melanocytes (Tyr:HRasV12G, INK4aΔ2/3) 
resulted in drastically different phenotypes when compared to constitutively active N-Ras 
(Tyr:NRasQ61K, INK4aΔ2/3).  N-Ras expressing mice developed highly pigmented and 
metastatic melanomas (311), while H-Ras expressing mice generated amelanotic and 
non-metastatic melanomas (312).  To determine if different Ras isoforms play different 
roles in transformation of melanocytes, all three Ras isoforms need to be studied in a 
conditional setting.  While the mouse model used in this thesis employs the K-RasG12D 
allele to induce Ras activation, the use of an inducible N-RasG12D allele would help 
determine if p16Ink4a loss cooperates with N-Ras more effectively than K-Ras and if N-
Ras activating mutations produce a different outcome than K-Ras activation.  Recently, a 
mouse model using B-RafV600E conditional allele with somatic loss of Pten (Tyr-CRE-
ERT2, B-RafV600E, PtenFlox ) generated highly pigmented and metastatic melanomas in vivo 
(72). The activation of N-Ras and B-Raf in melanocytes might alter different downstream 
effector pathways that are essential for melanocyte homeostasis, while K-Ras and H-Ras 
activation does not have these same effects.   
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While different RAS isoforms may have a role in the metastasis of melanoma, 
most probably there are other factors involved.  NEDD9 is a potential player in metastatic 
melanoma and NEDD9 expression increases as melanoma progresses(73); however we 
found that TKp16L/Lp53L/L tumors had an increase of NEDD9 expression (data not 
shown), but no metastases were observed.  This could be due to the fact that the rapid 
growth of the primary tumors (and the subsequent need to euthanize these mice due to 
IACUC regulations) limited the necessary time for metastasis development.  While 
NEDD9 is a potential player, other pathways could be involved in melanoma.  
 Recently, the serine threonine kinase LKB1 has gained recognition for its potent 
tumor suppressor mechanisms in lung cancer (402).  In mice, Lkb1 loss along with K-
RasG12D activation engendered metastatic lung cancer and also generated different 
histopathological subtypes of lung cancer: squamous cell carcinoma, adenocarcinoma and 
large cell undifferentiated carcinoma, suggesting that Lkb1 could be involved in 
initiation, differentiation and metastasis of lung cancer (403).  LKB1 germline mutations 
define the Peutz-Jeghers syndrome which is characterized by hamartomatous polyposis 
and mucocutaneous pigmentation mainly over the circum-oral region.  While Peutz-
Jeghers patients usually lose only one LKB1 allele explaining their moderate 
susceptibility to cancers when compared to the susceptibility of families with familial 
melanoma to develop cancers, the formation of pigmented macuoles suggests a potential 
role for homozygous deletion of LKB1 in melanoma formation.  However, studies of 
LKB1 in melanoma have only investigated point mutations found in LKB1 and found at 
most 5% of melanomas harbor deleterious mutations in this gene.  Recently, with the 
development of MLPA for detection of LKB1 deletion, an increase in LKB1 mutations 
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has been observed in approximately 20% of human melanoma cell lines (Monahan 
unpublished).  In addition, mice harboring a melanocyte specific inducible CRE allele 
(Tyr-CRE-ERT2) along with a conditional Lkb1L/L allele and K-RasG12D allele, were 
treated with 4-OHT and monitored for tumor development.  Surprisingly 2 out of 10 
mice, thus far, developed highly pigmented and metastatic melanomas within 24 weeks 
post-treatment, suggesting that different tumor suppressors could be involved in the 
metastasis of melanoma (Monahan unpublished). Future studies using the TyrCreERT2 
allele will determine the role of new players in melanoma, such as LKB1, to establish 
roles of other tumor suppressors in the pathogenesis of melanoma and to determine if 
they can generate metastasis in vivo. 
Conditional mouse models are generating better models of melanoma that will 
help decipher the roles of somatic deletions and activations of key players in melanoma.  
Here we describe a mouse model of melanoma which is based on somatic Ras activation 
and p16Ink4a loss, which are recognized as hallmarks of melanoma. Generating faithful 
models of melanoma will help discover and validate treatments for metastatic melanoma 
patients in the future. 
C. The potential applications of the TKp16 L/L p53L/L model 
Drug discovery and testing 
The development of anti-cancer therapies has been an arduous process with many 
hurdles along the way (reviewed in (404)).  The failure rate of new drugs entering clinical 
trials is not only high, but extremely costly for pharmaceutical companies. Furthermore, 
Phase I trial compounds benefit only 4% of patients, making treatment frustrating for 
oncologists.  A main obstacle in drug development is inadequate pre-clinical testing 
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methods. The pharmaceutical industry has heavily relied on xenograft models to 
determine efficacies of anti-cancer therapies in pre-clinical trials; however it is known 
that xenograft models do not inherently reflect a normal host microenvironment. 
Xenograft models involve injecting a homogenous population of cells into immune-
deficient mice (severe combined immunodeficient (SCID) or nude mice) which have 
profound defects in the immune system as well as in DNA repair.  Xenograft models fail 
to recapitulate both the complex nature of human cancers and the genetic diversity found 
in the human population.   
Historically alternative models, such as the genetically engineered mouse models 
of cancer, have not been used in the pharmaceutical industry primarily due to patents that 
make it difficult for companies to use these models as well as the cost of generating and 
maintaining these mice.  However, genetically engineered mouse models allow 
investigators to generate tumors that are heterogeneous, interact with surrounding 
microenvironment and stroma and the host immune system.  For these reasons, GEMMs 
could potentially become a platform for target validation, assessment of tumor response, 
discovery for biomarkers, modeling drug resistance and evaluation of drug toxicities.  
While genetically engineered mouse models have many advantages over xenograft 
models, there are still some disadvantages when using mouse models to study cancer and 
the effect of certain treatments. There are biological differences in mice versus humans, 
for example mice and humans have genes located on different chromosomes and do not 
share all of the same genes, (e.g. interleukin-8). In addition, mice have longer telomeres 
than humans which could alter secondary mutations found in cancer development. Lastly 
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laboratory mice are inbred; therefore they inherently lack the diversity found in the 
human population.     
Mouse models of melanoma are beginning to be used to determine new 
treatments, as well as to determine the efficacy of already established forms of treatment 
such as temozolomide.  The use of CDK inhibitors could be a potential anti-cancer 
therapy for melanomas, which either abrogate p16INK4a, an inhibitor of CDK4 and CDK6, 
or generate activating CDK4 mutations.  Surprisingly, treatment of Tyr:HRasV12G, 
Ink4aΔ2/3 melanoma bearing mice with a specific CDK4/6 inhibitor showed no response 
and the melanomas continued to proliferate in vivo, suggesting the tumors compensate by 
upregulating other CDKS (data not shown).  Further analysis of the CDK4/6 inhibitor in 
the Tyr:HRasV12G, Ink4aΔ2/3 mouse model of melanoma demonstrated that while CDK4/6 
might be a weak anti-cancer therapy, it could act as a both a radioprotectant and 
chemoprotectant and reduce severe side effects of radiation and chemotherapies (Johnson 
unpublished).   
Furthermore, farnesyltransferase inhibitors (FTIs) have been thought to target all 
RAS isoforms and to be potent anti-cancer therapies.  However both N-RAS and K-RAS 
are subjected to alternative post translation modifications and are able to localize to the 
cell membrane, while H-RAS is potently inhibited by FTIs.  The use of FTIs in H-RAS 
targeted diseases such as bladder cancer could be a potential therapy.  While H-RAS is 
not commonly mutated in cancer the Tyr:HRasV12G, Ink4aΔ2/3 mouse model of melanoma 
utilizes an active H-RasV12G transgene which could test the efficacy of FTIs.  
Tyr:HRasV12G, Ink4aΔ2/3 tumor bearing mice were treated with FTI for 2 weeks and 
modest response was observed with stable disease at about 2 weeks (data not shown).  
138 
 
However, treatment of FTI in combination with radiation, suggested that FTIs might 
desensitize tumors to radiation with an increase in proliferation when mice were treated 
with both FTI and radiation (Apisarnthanarax unpublished).  Mouse models not only are 
able to test target therapies, they are able to predict combinations of therapies and the 
interactions between novel agents and traditional therapies such as radiation.  
While the work described above is evidence that pharmaceutical drug testing is 
moving towards genetically engineered mouse models to evaluate the efficacy of drugs 
and discovery of new potential applications of drugs, the mouse model used harbors 
germline alleles.  In order to improve drug testing even further, better models of 
melanoma need to be employed.  The TKp16L/Lp53L/L model described in this work 
closely resembles the human form of melanoma, due to the somatic nature of the 
conditional alleles.  Therefore, future preclinical drug testing, evaluation and validation 
should be performed on the TKp16L/Lp53L/L model.   
In vivo imaging 
Mouse models have been an important tool in determining key factors in the 
initiation and development of cancer; however as the field progresses the list of players is 
becoming exhausted and screens identifying novel players commonly validate already 
known tumor suppressors or oncogenes.  While disheartening for some, this has opened 
opportunities in other areas of cancer research such as metastasis.  The ability to follow 
cancer progression can be accomplished through many different reporter constructs 
ranging from green fluorescent protein (GFP) to luciferase.  Many investigators in the 
melanoma field are attempting to use conditional alleles such as the Tyr-CRE-ERT2along 
with certain oncogenes and tumor suppressors and GFP to monitor all stages of tumor 
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progression from initiation to metastasis.  Staining of the vasculature using dextran red 
visualizes how tumor cells interact with the surrounding blood vessels and if they are 
traveling through the blood stream to reach distant sites. Using second harmonic 
generation to image the collagen fibers surrounding the primary tumor can be a useful 
tool to monitor tumor cell movement within the microenvironment.  In chapter 4, we 
showed that tumor development could be potentially followed through the use of GFP in 
the TKp16L/Lp53L/L conditional model; however because these melanomas lack the ability 
to metastasize, using these alleles will not work to visualize all the stages of melanoma 
progression.  Therefore, new tumor suppressors and oncogenes need to be implemented, 
such as LKB1, in order to follow the progression of melanoma.  The ability to visualize 
the progression of melanoma will not only allow us to see how cells travel to distant 
organs, but also how the microenvironment influences the growth of primary and 
metastatic tumors.   
D.  Evasion of the immune response: CD200 as a potential therapeutic target 
 The role of the immune system is intricately involved in the pathogenesis of 
melanoma.  One way melanoma evades an immune response is through expression of 
CD200, a negative regulator of the immune system (343). In addition to generating a 
novel conditional mouse model of melanoma, this work has demonstrated a causal role 
for CD200 in melanoma through abrogation of CD200 function in mixed lymphocytic 
reactions.  In chapter 5, we demonstrated that knockdown of CD200 in human melanoma 
cell lines resulted in a switch from Th2 to Th1 cytokines, which is indicative of an 
activated immune response and cytotoxic T cell response (354).  Moreover, 
immunohistochemical analysis demonstrated an increase of CD200 expression on 
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melanomas when compared to nevi and dysplastic nevi.  However, CD200 expression 
was still observed on nevi, suggesting it could play a role in the initiation of melanoma, 
maybe by helping these early lesions find a niche in the skin that is resistant to immune 
response. 
While we established a role for CD200 in melanoma, the ability to target CD200 
for a potential therapy has to be evaluated.  Recently, monoclonal antibodies targeting 
CD200 have been developed and, in order to test the efficacies of these antibodies, they 
will be added to mixed lymphocytic reactions with or without CD200 knockdown to see 
if they have an effect on a Th1 to Th2 switch.  In addition, human melanoma cells 
overexpressing CD200 could be used to evaluate anti-CD200 antibodies abilities to 
abrogate CD200 function.  The TKp16L/Lp53L/L and Tyr:HRasV12G, INK4aΔ2/3 mouse 
models of melanomas have been evaluated for CD200 expression (data not shown) and 
were found to be heterogeneous with some tumor derived cell lines showing high CD200 
and some low CD200 expression, making it difficult to determine if these in vivo models 
would be appropriate models to test the efficacies of the anti-CD200 antibodies.  
However, melanoma is heterogeneous and even human melanoma cell lines have a range 
of CD200 expression; therefore these mouse models could be used and put in randomized 
trials to see if tumors respond.  Analysis of responders and non-responders could reveal 
novel genetic factors involved in the modulation of the immune response.  Furthermore, 
immunohistochemical analysis of infiltrating T cells in the tumor could determine if 
abrogation of CD200 function causes a decrease in an immunosuppressive 
microenvironment usually found in melanoma.   
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In addition, there is much unknown about the downstream signaling that occurs 
through the CD200R.  While it is thought that the NPXY signaling motif is 
phosphorylated by Dok1 and Dok2 and this phosphorylation is mediated through Src 
family of kinases, side effects of Src kinase inhibitors have not been related to 
upregulation of the immune response in treated patients, suggesting that Src family of 
kinases do not regulated this process and other kinases may be playing a role in CD200 
receptor signaling.   
With the many failures in the clinical treatment of melanoma patients, anti-CD200 
antibodies are an attractive option for a Phase I trial for metastatic melanoma patients.  
The work describe in Chapter 5 has established a base for a new targeted therapy for 
melanoma patients; however the efficacy of anti-CD200 antibodies needs to be 
determined.  In the future, this work on CD200 and the immune system will hopefully 
translate to the clinic for treatment of melanoma patients. 
E.  Summary: Contributions to Melanoma Research 
Generating new mouse models of melanoma and studying the role of the immune 
response in melanoma are two exciting areas of research in the melanoma field.  Mouse 
models of melanoma have become highly sophisticated with the emergence of a 
melanocyte-specific inducible CRE allele (Tyr-CRE-ERT2) which has engendered two 
new conditional models of melanoma.  Conditional alleles provide insight into the 
somatic nature of tumor suppressors and oncogenes in the context of melanocytes while 
also faithfully recapitulating human melanoma.  While the Tyr-CRE-ERT2, B-RafV600E, 
PtenFlox model generated pigmented and metastatic melanomas (72), the TKp16L/Lp53L/L 
model did not, suggesting either that K-Ras activation is not as oncogenic as B-Raf 
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activation or that other potential targets are involved in melanoma metastasis.  The 
TKp16L/Lp53L/L model is a platform for other targets that could be playing a role in 
melanoma pathogenesis, such as LKB1, HIF1α and HIF2α.  Moreover, the 
TKp16L/Lp53L/L tumor bearing mice could be treated with new therapeutic agents, such as 
anti-CD200 antibodies, along with conventional treatments to determine the efficacy of 
certain therapies in this model.  The work presented in this thesis has made valuable 
contributions to the field of melanoma research by generating a novel conditional mouse 
model of melanoma and identifying a key player in immune evasion of melanoma. 
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